Document:

exv10w47

EXHIBIT
10.47

TERM LOAN AND SECURITY AGREEMENT

THIS TERM LOAN AND SECURITY AGREEMENT (as the same may be amended, supplemented, restated or
otherwise modified from time to time, the “Agreement”), dated as of                     , 2009 (“Effective
Date”), is made and entered into by and among (a) NxStage Medical, Inc., a company organized and
existing under the laws of Delaware, United States of America (“NxStage Medical”), EIR Medical,
Inc. (“EIR”), a company organized and existing under the laws of Massachusetts, United States of
America, Medisystems Services Corporation (“Medisystems Services”), a company organized and
existing under the laws of Nevada, United States of America, Medisystems Corporation
(“Medisystems”), a company organized and existing under the laws of Washington, United States of
America, each as a borrower hereunder (NxStage Medical, EIR, Medisystems Services, and Medisystems
being referred to collectively herein as the “Borrowers” and each as a “Borrower”); (b) Medimexico
s. de R.L. de C.V., a company organized and existing under the laws of Mexico, NxStage Verwaltungs
GmbH, a company organized and existing under the laws of Germany, NxStage GmbH & Co. KG, a company
organized and existing under the laws of Germany, Medisystems Europe S.p.A, a company organized and
existing under the laws of Italy, each as a guarantor hereunder and solely for the purposes of
Article 9 hereof (Medimexico, NxStage Verwaltungs, NxStage GmbH, and Medisystems Europe being
referred to collectively herein as the “Guarantors” and each as a “Guarantor”), and (c) Asahi Kasei
Kuraray Medical Co., Ltd., a corporation organized and existing under the law of Japan, as the
lender hereunder (“Asahi”). Unless otherwise set forth herein, the Borrowers and the Guarantors
are referred to collectively herein as “NxStage” and the Borrowers and Asahi are referred to
collectively herein as the “Parties” and each as a “Party.”

RECITALS

WHEREAS, NxStage Medical and Asahi entered into the “Letter of Intent” dated September 19, 2008
(“LOI”) in order to negotiate agreements between the Parties under which NxStage Medical and Asahi
intend to establish a strategic alliance in the field of hemodialysis, hemofiltration,
hemodiafiltration, and/or ultrafiltration therapies (“Extracorporeal Therapies”) to capitalize on
Asahi’s membrane technology and market presence and on NxStage Medical’s market presence and
experience in disposables and machine technology in the field of Extracorporeal Therapies; and

WHEREAS, as a part of such strategic alliance, and in connection with and as a condition to
entering into the “Technology and Trademark License Agreement,” NxStage has requested that Asahi
makes available to the Borrowers the term loan as described herein, and Asahi is willing to make
such loan to the Borrowers under the terms and conditions herein set forth.

NOW, THEREFORE, in consideration of the premises and the agreements, provisions and covenants
herein contained, NxStage and Asahi agree as follows:

ARTICLE 1 — DEFINITIONS

	1.1	 	Certain Defined Terms.

	 	 	The following terms have the following meanings:

 

 

	(1)	 	“Accounts” means collectively any “account” (as defined in Article 9 of the UCC), any
accounts receivable (whether in the form of payments for services rendered or goods sold,
rents, license fees or otherwise), any “payment intangibles” (as defined in Article 9 of the
UCC), and IP Proceeds and all other rights to payment and/or reimbursement of every kind and
description, whether or not earned by performance.
	 
	(2)	 	“Account Debtors” means “account debtor”, as defined in Article 9 of the UCC, and any other
obligor in respect of an Account.
	 
	(3)	 	“Affiliate” means, with respect to any Person, any other Person directly or indirectly
controlling, controlled by, or under common control with, such Person, where “control” means
direct or indirect beneficial ownership of fifty percent (50%) or more of the voting stock or
equity of or by such other Person, or fifty percent (50%) or more of the interest in the
income of such other Person.
	 
	(4)	 	“Anti-Terrorism Laws” means any Laws relating to terrorism or money laundering, including
Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the Laws
comprising or implementing the Bank Secrecy Act, and the Laws administered by OFAC.
	 
	(5)	 	“Asset Disposition” means any sale, lease, license, transfer, assignment or other consensual
disposition by NxStage of any asset.
	 
	(6)	 	“Blocked Person” means any Person: (a) listed in the annex to, or is otherwise subject to the
provisions of, Executive Order No. 13224, (b) owned or controlled by, or acting for or on
behalf of, any Person that is listed in the annex to, or is otherwise subject to the
provisions of, Executive Order No. 13224, (c) with which Asahi is prohibited from dealing or
otherwise engaging in any transaction by any Anti-Terrorism Law, (d) that commits, threatens
or conspires to commit or supports “terrorism” as defined in Executive Order No. 13224, or (e)
that is named a “specially designated national” or “blocked person” on the most current list
published by OFAC or other similar list or is named as a “listed person” or “listed entity” on
other lists made under any Anti-Terrorism Law.
	 
	(7)	 	“Business Day” means any day except a Saturday, Sunday or other day on which either the New
York Stock Exchange is closed, or on which commercial banks in New York City are authorized by
law to close.
	 
	(8)	 	“CERCLA” means the Comprehensive Environmental Response, Compensation and Liability Act of
1980.
	 
	(9)	 	“Change of Control” means, as to any Person, any one of the following events: (i) any Person
or two or more Persons acting in concert shall have acquired beneficial ownership, directly or
indirectly, of more than fifty percent (50%) of the total voting power of the stock then
outstanding of such Person normally entitled to vote in elections of directors of such Person;
(ii) such Person consolidates with or merges into another entity, or any entity consolidates
with or merges into such Person, in either event pursuant to a transaction in which more than
fifty percent (50%) of the total voting power of the stock outstanding of the surviving entity
normally entitled to vote in elections of directors of the surviving entity is not held by the
parties holding at least fifty percent (50%) of such total voting power of

2

 

	 	 	such Person preceding such consolidation or merger; or (iii) such Person conveys, transfers or
leases all or substantially all of its assets to a another entity not an Affiliate of such Person.
Notwithstanding the foregoing, the acquisition/ownership of more than 50% by any Existing
Stockholder or two or more Existing Stockholders (meaning any stockholder of NxStage Medical as of
the Effective Date which beneficially owns, together with its Affiliates, more than five percent
(5%) of the outstanding capital stock of NxStage Medical as of the Effective Date) will not
constitute a Change of Control. As soon as available after the Effective Date, NxStage shall
provide Asahi with the list of the Existing Stockholders.
	 
	(10)	 	“Closing Date” means the date that is the date on which the Transaction Funds are released by
the Funds Escrow Agent as described in Section 3 of the Escrow Agreement.
	 
	(11)	 	“Code” means the Internal Revenue Code of 1986, as amended from time to time.
	 
	(12)	 	“Collaboration Agreement” means the NxStage & Asahi Collaboration Agreement, dated as of the
Effective Date, entered into by NxStage Medical and Asahi, as the same may be amended,
modified, or supplemented from time to time.
	 
	(13)	 	“Collateral” means all property, now existing or hereafter acquired, that is mortgaged or
pledged to, or purported to be subjected to a Lien in favor of, Asahi pursuant to this
Agreement and the Security Documents, including, without limitation, all of the property
described in Schedule 7.1 hereto.
	 
	(14)	 	“Contingent Obligation” means, with respect to any Person, any direct or indirect liability
of such Person: (a) with respect to any Debt of another Person (a “Third Party Obligation”) if
the purpose or intent of such Person incurring such liability, or the effect thereof, is to
provide assurance to the obligee of such Third Party Obligation that such Third Party
Obligation will be paid or discharged, or that any agreement relating thereto will be complied
with, or that any holder of such Third Party Obligation will be protected, in whole or in
part, against loss with respect thereto; (b) under any swap agreement or other derivative
instrument, to the extent not yet due and payable; (c) to make take-or-pay or similar payments
if required regardless of nonperformance by any other party or parties to an agreement
(excluding purchase contracts for a specified amount of goods at a specified price in the
Ordinary Course of Business and consistent with past practices); or (d) for any obligations of
another Person pursuant to any guaranty or pursuant to any agreement to purchase, repurchase
or otherwise acquire any obligation or any property constituting security therefor, to provide
funds for the payment or discharge of such obligation or to preserve the solvency, financial
condition or level of income of another Person. The amount of any Contingent Obligation shall
be equal to the amount of the obligation so guarantied or otherwise supported or, if not a
fixed and determinable amount, the maximum amount so guarantied or otherwise supported.
	 
	(15)	 	“Controlled Group” means all members of any group of corporations and all members of a group
of trades or businesses (whether or not incorporated) under common control which, together
with NxStage, are treated as a single employer under Section 414(b), (c), (m) or (o) of the
Code or Section 4001(b) of ERISA.
	 
	(16)	 	“Debt” of a Person means at any date, without duplication, (a) all obligations of such Person
for borrowed money, (b) all obligations of such Person evidenced by bonds,

3

 

	 	 	debentures, notes or other similar instruments, (c) all obligations of such Person to pay the
deferred purchase price of property or services, except trade accounts payable arising and paid on
a timely basis and in the Ordinary Course of Business, (d) all capital leases of such Person, (e)
all non-contingent obligations of such Person to reimburse any bank or other Person in respect of
amounts paid under banker’s acceptance or similar instrument, (f) all equity securities of such
Person subject to repurchase or redemption otherwise than at the sole option of such Person, (g)
all obligations secured by a Lien on any asset of such Person, whether or not such obligation is
otherwise an obligation of such Person, (h) “earnouts”, purchase price adjustments, profit sharing
arrangements, deferred purchase money amounts and similar payment obligations or continuing
obligations of any nature of such Person arising out of purchase and sale contracts; (i) all Debt
of others guaranteed by such Person; (j) off-balance sheet liabilities and/or Pension Plan
liabilities or Multiemployer Plan liabilities of such Person; and (k) obligations arising under
bonus, deferred compensation, incentive compensation or similar arrangements, other than those
arising in the Ordinary Course of Business. Without duplication or limitation of any of the
foregoing, Debt of NxStage shall include the Term Loan.
	 
	(17)	 	“Default” means any condition or event which with the giving of notice or lapse of time or
both would, unless cured or waived, become an Event of Default.
	 
	(18)	 	“Deposit Account” means a “deposit account” (as defined in Article 9 of the UCC).
	 
	(19)	 	“Dollars” or “$” means the lawful currency of the United States of America.
	 
	(20)	 	“DSU License Agreement” means the License Agreement, dated as of June 1, 2007, entered into
by DSU Medical Corporation, as licensor, and Medisystems, as licensee, as amended, modified,
and supplemented as of the Effective Date.
	 
	(21)	 	“Environmental Laws” means any and all applicable Laws relating to the environment or the
effect of the environment on human health or to emissions, discharges or releases of
pollutants, contaminants, medical wastes, Hazardous Materials or wastes into the environment,
including ambient air, surface water, ground water or land, or otherwise relating to the
manufacture, processing, distribution, use, treatment, storage, disposal, transport or
handling of pollutants, contaminants, medical wastes, Hazardous Materials or wastes or the
clean-up or other remediation thereof.
	 
	(22)	 	“ERISA” means the Employee Retirement Income Security Act of 1974, as the same may be
amended, modified or supplemented from time to time, and any successor statute thereto, and
any and all rules or regulations promulgated from time to time thereunder.
	 
	(23)	 	“Escrow Agreement” means the Document Escrow Agreement, dated as of May 13, 2009, entered
into by NxStage Medical and Asahi.
	 
	(24)	 	“Event of Default” has the meaning set forth in Section 8.1.
	 
	(25)	 	“FF&E” means all present and future Field Equipment upon which a first priority security
interest may be perfected under the UCC by the filing of a financing statement and which filed
security interest cannot be primed by some other means of perfection under the UCC, and
specifically excluding any vehicles and any goods or other personal property upon

4

 

	 	 	which a lien or security interest may be acquired or perfected under laws other than the UCC.
	 
	(26)	 	“Field Equipment” means only System One cyclers, Pure Flow systems and all components
thereof, and similar products that are updates thereto or developments thereon, which are
leased to end users.
	 
	(27)	 	“Financing Documents” means this Agreement and the Note, as any or all of the same may be
amended, supplemented, restated or otherwise modified from time to time.
	 
	(28)	 	“GAAP” means generally accepted accounting principles set forth from time to time in the
opinions and pronouncements of the Accounting Principles Board and the American Institute of
Certified Public Accountants and statements and pronouncements of the Financial Accounting
Standards Board (or agencies with similar functions of comparable stature and authority within
the United States accounting profession), which are applicable to the circumstances as of the
date of determination.
	 
	(29)	 	“Governmental Authority” means any nation or government, any state or other political
subdivision thereof, and any agency, department or Person exercising executive, legislative,
judicial, regulatory or administrative functions of or pertaining to government and any
corporation or other Person owned or controlled (through stock or capital ownership or
otherwise) by any of the foregoing, whether domestic or foreign.
	 
	(30)	 	“Hazardous Materials” means (a) any “hazardous substance” as defined in CERCLA, (b) any
“hazardous waste” as defined by the Resource Conservation and Recovery Act, (c) asbestos, (d)
polychlorinated biphenyls, (e) petroleum, its derivatives, by-products and other hydrocarbons,
(f) mold, and (g) any other pollutant, medical waste, toxic, radioactive, caustic or otherwise
hazardous substance regulated under Environmental Laws.
	 
	(31)	 	“Intellectual Property” means, with respect to any Person, all patents, patent applications
and like protections, including improvements, divisions, continuation, renewals, reissues,
extensions and continuations in part of the same, trademarks, trade names, trade styles, trade
dress, service marks, logos and other business identifiers and, to the extent permitted under
applicable law, any applications therefor, whether registered or not, and the goodwill of the
business of such Person connected with and symbolized thereby, copyright rights, copyright
applications, copyright registrations and like protections in each work of authorship and
derivative works, whether published or unpublished, technology, know-how and processes,
operating manuals, trade secrets, computer hardware and software, rights to unpatented
inventions and all applications and licenses therefor, used in or necessary for the conduct of
business by such Person and all claims for damages by way of any past, present or future
infringement of any of the foregoing.
	 
	(32)	 	“Investment” means any investment in any Person, whether by means of acquiring (whether for
cash, property, services, securities or otherwise) or holding securities, capital
contributions, loans, time deposits, advances, guaranties or otherwise. The amount of any
Investment shall be the original cost of such Investment plus the cost of all additions
thereto, without any adjustments for increases or decreases in value, or write-ups,
write-downs or write-offs with respect thereto.

5

 

	(33)	 	“IP Proceeds” means all Accounts, General Intangibles (including Payment Intangibles),
license and royalty fees and other revenues, Proceeds, income or rights to payment arising out
of or relating to the use, sale, licensing, financing or disposition of any of the
Intellectual Property (nothing herein implying the secured party’s consent to any such sale,
licensing, financing or disposition).
	 
	(34)	 	“Laws” means any and all federal, state, provincial, territorial, local and foreign statutes,
laws, judicial decisions, regulations, ordinances, rules, judgments, orders, decrees, codes,
injunctions, governmental agreements and governmental restrictions, whether now or hereafter
in effect, which are applicable to the Borrowers in any particular circumstance. “Laws”
includes, without limitation, Environmental Laws.
	 
	(35)	 	“Lien” means, with respect to any asset, any mortgage, lien, pledge, charge, security
interest or encumbrance of any kind, or any other type of preferential arrangement that has
the practical effect of creating a security interest, in respect of such asset. For the
purposes of this Agreement and the other Financing Documents, the Borrowers shall be deemed to
own subject to a Lien any asset which it has acquired or holds subject to the interest of a
vendor or lessor under any conditional sale agreement, capital lease or other title retention
agreement relating to such asset.
	 
	(36)	 	“Litigation” means any action, suit or proceeding before any court, mediator, arbitrator or
Governmental Authority.
	 
	(37)	 	“Material Adverse Effect” means with respect to any event, act, condition or occurrence of
whatever nature (including any adverse determination in any litigation, arbitration, or
governmental investigation or proceeding), whether singly or in conjunction with any other
event or events, act or acts, condition or conditions, occurrence or occurrences, whether or
not related, a material adverse change in, or a material adverse effect upon, any of (i) the
rights and remedies of Asahi under any Financing Document, or the ability of any Borrower to
perform any of its material obligations under any Financing Document, (ii) the legality,
validity or enforceability of any Financing Document, (iii) the existence, perfection or
priority of any security interest in any material Collateral granted in any Financing
Document, or (iv) the value of any material Intellectual Property or material Collateral.
	 
	(38)	 	“Material Contracts” means (a) employment agreements covering the management of the
Borrowers, (b) collective bargaining agreements or other similar labor agreements covering any
employees of the Borrowers, (c) agreements for managerial, consulting or similar services to
which any Borrower is a party or by which it is bound (other than those agreements with
employees and other regularly provided legal and accounting services), (d) agreements
regarding any Borrower, its assets or operations or any investment therein to which any of its
equity holders is a party or by which it is bound, (e) real estate leases, Intellectual
Property licenses, agreements providing for the sale or transfer of rights to Intellectual
Property providing for ongoing royalty or similar payment to the seller or transferor, or
other lease or license agreements to which any Borrower is a party, either as lessor or
lessee, or as licensor or licensee (other than “shrinkwrap” licenses or other licenses arising
from the purchase of “off the shelf” products), or seller/transferor or buyer/transferee, (f)
customer, distribution, marketing or supply agreements to which any

6

 

	 	 	Borrower is a party that require payment of more than $2,000,000 in any year, (g) partnership
agreements to which any Borrower is a general partner or joint venture agreements to which any
Borrower is a party, (h) third party billing arrangements to which any Borrower is a party, or (i)
any other agreements or instruments to which any Borrower is a party, and the breach,
nonperformance or cancellation of which, or the failure of which to renew, could reasonably be
expected to have a Material Adverse Effect, provided that, in each case with respect to the
preceding clauses (a), (c), (d) and (e) such agreement or contract requires payment of more than
$250,000 in any year.
	 
	(39)	 	“Maturity Date” means the earlier of May 31, 2013 and the date that any Change of Control of
NxStage Medical occurs.
	 
	(40)	 	“Maximum Lawful Rate” has the meaning set forth in Section 2.4.
	 
	(41)	 	“Multiemployer Plan” means a multiemployer plan within the meaning of Section 4001(a)(3) of
ERISA.
	 
	(42)	 	“Note” shall have the meaning set forth in Section 2.3.
	 
	(43)	 	“Obligations” means all obligations, liabilities and indebtedness (monetary (including
post-petition interest, whether or not allowed) or otherwise) of NxStage under this Agreement
or any other Financing Document, in each case howsoever created, arising or evidenced, whether
direct or indirect, absolute or contingent, now or hereafter existing, or due or to become due
(but not including obligations under any stock issued to Asahi pursuant to Section 2.1(b)).
	 
	(44)	 	“OFAC” means the U.S. Department of Treasury Office of Foreign Assets Control.
	 
	(45)	 	“OFAC Lists” means, collectively, the Specially Designated Nationals and Blocked Persons List
maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001)
and/or any other list of terrorists or other restricted Persons maintained pursuant to any of
the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.
	 
	(46)	 	“Ordinary Course of Business” means, in respect of any transaction involving any Borrower,
the ordinary course of business of the Borrower, as conducted by the Borrower in accordance
with past practices.
	 
	(47)	 	“Organizational Documents” means, with respect to any Person other than a natural person, the
documents by which such Person was organized (such as a certificate of incorporation,
certificate of limited partnership or articles of organization, and including, without
limitation, any certificates of designation for preferred stock or other forms of preferred
equity) and which relate to the internal governance of such Person (such as by-laws, a
partnership agreement or an operating, limited liability or members agreement).
	 
	(48)	 	“PBGC” means the Pension Benefit Guaranty Corporation and any Person succeeding to any or all
of its functions under ERISA.

7

 

	(49)	 	“Pension Plan” means an employee pension benefit plan (other than a Multiemployer Plan) which
is covered by Title IV of ERISA or subject to the minimum funding standards under Section 412
of the Code.
	 
	(50)	 	“Permits” means all governmental licenses, authorizations, provider numbers, supplier
numbers, registrations, permits, drug or device authorizations and approvals, certificates,
franchises, qualifications, accreditations, consents and approvals required under all
applicable Laws and required in order to carry on its business as now conducted.
	 
	(51)	 	“Permitted Acquisition” means (i) the acquisition of all or substantially all of the assets
of another Person, or of a business line or a unit or division of another Person or (ii) a
merger, consolidation, or amalgamation of any Borrower (A) that is a transaction among one or
more of the Borrowers and any other Borrower or Borrowers or (B) is among one or more of the
Borrowers and one or more other Persons and results in one or more Borrowers as the surviving
entity or entities; provided, that after giving effect to such acquisition, merger,
consolidation, or amalgamation, no Event of Default has occurred and is continuing or would
exist after giving effect to such acquisition, merger, consolidation, or amalgamation, and
that, after giving effect to such acquisition, consolidation, or amalgamation, there is no
Change of Control of NxStage Medical.
	 
	(52)	 	“Permitted Asset Dispositions” means the following Asset Dispositions provided that at the
time of such Asset Disposition, no Default or Event of Default exists or would result from
such Asset Disposition: (i) dispositions of Inventory and FF&E in the Ordinary Course of
Business and not pursuant to any bulk sale, (ii) the granting of non-exclusive licenses in the
Ordinary Course of Business, (iii) Asset Dispositions of obsolete or worn out property, (iv)
other Asset Dispositions of up to $2,000,000 in the aggregate per fiscal year, and (v) other
dispositions approved by Asahi.
	 
	(53)	 	“Permitted Contest” means, with respect to any tax obligation or other obligation allegedly
or potentially owing from any Borrower to any governmental tax authority or other third party,
a contest maintained in good faith by appropriate proceedings promptly instituted and
diligently conducted and with respect to which such reserve or other appropriate provision, if
any, as shall be required in conformity with GAAP shall have been made on the books and
records and financial statements of any Borrower; provided, however, that (a) compliance with
the obligation that is the subject of such contest is effectively stayed during such
challenge; (b) no Borrower’s title to, and its right to use, the Collateral is adversely
affected thereby and Asahi’s Lien and priority on the Collateral are not adversely affected,
altered or impaired thereby; (c) the Collateral or any part thereof or any interest therein
shall not be in any danger of being sold, forfeited or lost by reason of such contest; and (d)
upon a final determination of such contest, the applicable Borrower or Borrowers shall
promptly comply with the requirements thereof.
	 
	(54)	 	“Permitted Contingent Obligations” means: (a) Contingent Obligations arising in respect of
the Debt under the Financing Documents ; (b) Contingent Obligations outstanding on the date of
this Agreement and set forth on Schedule 5.1 (including any refinancings or extensions
thereof, but not including any increases in the amount thereof); (c) Contingent Obligations
incurred in the Ordinary Course of Business with respect to surety and appeal bonds,
performance bonds, customs bonds and other similar obligations

8

 

	 	 	with respect to bonds provided to utilities with respect to utility services provided to Borrowers
in the Ordinary Course of Business, not to exceed $500,000 in the aggregate at any time
outstanding; (d) Contingent Obligations resulting from endorsements for collections or deposits in
the Ordinary Course of Business; (e) Contingent Obligations arising from warranty and indemnity
claims resulting from Permitted Asset Dispositions; (f) Contingent Obligations arising from a
Permitted Contest, (g) Contingent Obligations constituting Permitted Liens; (h) Contingent
Obligations, if any, arising under swap agreements or other derivative instruments entered into by
Borrowers; (i) Contingent Obligations on account of reimbursement obligations under letters of
credit that constitute Permitted Indebtedness; and (j) all other Contingent Obligations not
permitted by the preceding clauses but incurred in the Ordinary Course of Business, not to exceed
$250,000 in the aggregate at any time outstanding.
	 
	(55)	 	“Permitted Distributions” means the following Restricted Distributions: (a) dividends by any
Subsidiary of a Borrower to such Borrower; (b) dividends payable solely in common stock; and
(c) repurchases of stock of former employees, directors or consultants pursuant to stock
repurchase agreements so long as an Event of Default does not exist at the time of such
repurchase and would not exist after giving effect to such repurchase, provided that such
repurchases do not exceed $250,000 in the aggregate per fiscal year.
	 
	(56)	 	“Permitted Indebtedness” means: (a) the Obligations; (b) Debt incurred as a result of
endorsing negotiable instruments received in the Ordinary Course of Business; (c) purchase
money Debt not to exceed $10,000,000 at any time (whether in the form of a loan or a lease)
used solely to acquire equipment used in the Ordinary Course of Business and secured only by
such equipment and related attachments (including any refinancing or extensions thereof, but
not including any increases in the amount thereof); (d) Debt existing on the date of this
Agreement and described on Schedule 5.1 (including any refinancings or extensions
thereof, but not including any increases in the amount thereof); (e) Debt, if any, arising
under swap agreements or other derivative instruments; (f) trade accounts payable arising and
paid on a timely basis and in the Ordinary Course of Business and obligations to employees,
consultants, independent contractors, and professionals in the Ordinary Course of Business;
(g) Debt in the form of insurance premiums financed through the applicable insurance company;
(h) obligations in the form of letters of credit existing on the Closing Date; (i) Debt among
the Borrowers and Guarantors; (j) reimbursement obligations in connection with letters of
credit up to $1,500,000 in the aggregate at any one time; and (k) other Debt not permitted by
the preceding clauses in an amount not exceeding $30,000,000 in the aggregate, at any time.
	 
	(57)	 	“Permitted Investments” means: (a) Investments shown on Schedule 5.5 and existing on
the Closing Date; (b) (i) cash equivalents, and (ii) any similar short term Investments
permitted by the Borrowers’ investment policies, as amended from time to time, provided that
any new investment policy (and any material amendments to the current policy or any new
policy, including the current policy) has been approved in writing by Asahi in its reasonable
discretion; (c) Investments consisting of the endorsement of negotiable instruments for
deposit or collection or similar transactions in the Ordinary Course of Business; (d)
Investments consisting of loans to employees, officers or directors relating to the purchase
of equity securities of any Borrower pursuant to employee stock purchase plans or agreements
approved by the applicable Borrower’s Board of Directors (or other

9

 

	 	 	governing body), but the aggregate of all such loans outstanding may not exceed $250,000 at any
time; (e) Investments consisting of relocation loans or advances to current or prospective
employees in an amount not to exceed $200,000 in the aggregate at any time; (f) Investments
(including debt obligations) received in connection with the bankruptcy or reorganization of
customers or suppliers and in settlement of delinquent obligations of, and other disputes with,
customers or suppliers arising in the Ordinary Course of Business; (g) Investments consisting of
notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers
who are not Affiliates, in the Ordinary Course of Business; provided that this subpart (g) shall
not apply to Investments of any Borrower in any of its Subsidiaries; (h) Investments consisting of
Deposit Accounts or Securities Accounts permitted under Section 5.7; (i) Investments by any
Borrower in any Borrower or Guarantor; (j) Investments consisting of the acquisition of all or
substantially all of the capital stock of another Person or the formation of a new Subsidiary
provided that after giving effect to such acquisition, no Event of Default has occurred and is
continuing or would exist after giving effect to such acquisition, there shall be no decrease in
NxStage’s tangible net worth after giving effect to such acquisition (as confirmed to Asahi
pursuant to a written certificate from a Responsible Officer of NxStage Medical), the aggregate
amount of cash paid for such acquisitions (together with all Permitted Acquisitions) shall not
exceed $5,000,000 per year or $10,000,000 in the aggregate and the NxStage shall have complied
with Section 5.5(b); and (k) other Investments in an amount not exceeding $250,000 in the
aggregate, at any time.
	 
	(58)	 	“Permitted Liens” means: (a) deposits or pledges of cash to secure obligations under
workmen’s compensation, social security or similar laws, or under unemployment insurance (but
excluding Liens arising under ERISA) pertaining to NxStage’s employees, if any; (b) deposits
or pledges of cash to secure bids, tenders, contracts (other than contracts for the payment of
money or the deferred purchase price of property or services), leases, statutory obligations,
surety and appeal bonds and other obligations of like nature arising in the Ordinary Course of
Business; (c) carrier’s, warehousemen’s, mechanic’s, workmen’s, materialmen’s or other like
Liens on Collateral arising in the Ordinary Course of Business with respect to obligations
which are not due, or which are being contested pursuant to a Permitted Contest; (d) Liens on
Collateral for taxes or other governmental charges not at the time delinquent or thereafter
payable without penalty or the subject of a Permitted Contest; (e) attachments, appeal bonds,
judgments and other similar Liens on Collateral, for sums not exceeding $250,000 in the
aggregate arising in connection with court proceedings; provided, however, that the execution
or other enforcement of such Liens is effectively stayed and the claims secured thereby are
the subject of a Permitted Contest; (f) Liens and encumbrances in favor of Asahi under the
Financing Documents; (g) Liens on assets to the extent existing on the Effective Date and set
forth on Schedule 5.2; (h) any Lien on any assets securing Debt permitted under
subpart (c) of the definition of Permitted Indebtedness, provided, however, that such Lien
attaches concurrently with or within twenty (20) days after the acquisition thereof; (i) any
immaterial real estate easement, right of way, restriction, defect or irregularity in title;
(j) Liens on cash in a segregated account in an amount not to exceed $1,500,000 to secure Debt
permitted pursuant to subpart (j) of Permitted Indebtedness; and (k) Liens on assets other
than Collateral securing Debt permitted pursuant to subpart (k) of Permitted Indebtedness.

10

 

	(59)	 	“Person” means any natural person, corporation, limited liability company, professional
association, limited partnership, general partnership, joint stock company, joint venture,
association, company, trust, bank, trust company, land trust, business trust or other
organization, whether or not a legal entity, and any Governmental Authority.
	 
	(60)	 	“Responsible Officer” means any of the Chief Executive Officer or Chief Financial Officer of
NxStage Medical.
	 
	(61)	 	“Restricted Distribution” means as to any Person (a) any dividend or other distribution
(whether in cash, securities or other property) on any equity interest in such Person (except
those payable solely in its equity interests of the same class), (b) any payment on account of
(i) the purchase, redemption, retirement, defeasance, surrender, cancellation, termination or
acquisition of any equity interests in such Person or any claim respecting the purchase or
sale of any equity interest in such Person or (ii) any option, warrant or other right to
acquire any equity interests in such Person, (c) any management fees, salaries or other fees
or compensation to any Person other than NxStage Medical holding an equity interest in the
Borrowers (other than (A) payments of ordinary compensation consistent with past practices to
individuals, (B) directors fees, (C) the issuance of stock options or restricted stock to
employees and board members, and (D) advances and reimbursements to employees or directors,
all in the Ordinary Course of Business and consistent with past practices), or (d) any lease
or rental payments to an Affiliate or Subsidiary of the Borrowers that is not a Borrower or a
Guarantor, except allocations or other payments at fair market value reasonably proportionate
to actual use.
	 
	(62)	 	“SEC” means the United States Securities and Exchange Commission.
	 
	(63)	 	“Securities Account” means a “securities account” (as defined in Article 9 of the UCC), an
investment account, or other account in which Investment Property or Securities are held or
invested for credit to or for the benefit of Borrowers.
	 
	(64)	 	“Security Document” means this Agreement and any other agreement, document or instrument
executed concurrently herewith or at any time hereafter pursuant to which Asahi or any other
Person either (a) guaranties payment or performance of all or any portion of the Obligations,
and/or (b) provides, as security for all or any portion of the Obligations, a Lien on any of
its assets in favor of Asahi for its own benefit, as any or all of the same may be amended,
supplemented, restated or otherwise modified from time to time.
	 
	(65)	 	“Solvent” means, with respect to any Person, that such Person (a) owns and will own assets
the fair saleable value of which are (i) greater than the total amount of its liabilities
(including Contingent Obligations) required to be classified upon a balance sheet as
liabilities in accordance with GAAP, and (ii) greater than the amount that will be required to
pay the probable liabilities of its then existing debts as they become absolute and matured
considering all financing alternatives and potential asset sales reasonably available to it;
(b) has capital that is not unreasonably small in relation to its business as presently
conducted or after giving effect to any contemplated transaction; and (c) does not intend to
incur and does not believe that it will incur debts beyond its ability to pay such debts as
they become due.

11

 

	(66)	 	“Subsidiary” means, with respect to any Person, (a) any corporation of which an aggregate of
more than fifty percent (50%) of the outstanding capital stock having ordinary voting power to
elect a majority of the board of directors of such corporation (irrespective of whether, at
the time, capital stock of any other class or classes of such corporation shall have or might
have voting power by reason of the happening of any contingency) is at the time, directly or
indirectly, owned legally or beneficially by such Person or one or more Subsidiaries of such
Person, or with respect to which any such Person has the right to vote or designate the vote
of more than fifty percent (50%) of such capital stock whether by proxy, agreement, operation
of law or otherwise, and (b) any partnership or limited liability company in which such Person
and/or one or more Subsidiaries of such Person shall have an interest (whether in the form of
voting or participation in profits or capital contribution) of more than fifty percent (50%)
or of which any such Person is a general partner or may exercise the powers of a general
partner. Unless the context otherwise requires, each reference to a Subsidiary shall be a
reference to a Subsidiary of Borrowers.
	 
	(67)	 	“Taxes” has the meaning set forth in Section 2.5.
	 
	(68)	 	“Technology Trademark and License Agreement” means that Technology and Trademark License
Agreement, dated as of the Effective Date, entered into by NxStage Medical and Asahi, as the
same may be amended, modified, or supplemented from time to time.
	 
	(69)	 	“Term Loan” has the meaning set forth in Section 2.1(a).
	 
	(70)	 	“UCC” means the Uniform Commercial Code of the State of New York or of any other state the
laws of which are required to be applied in connection with the perfection of security
interests in any Collateral.
	 
	(71)	 	“United States” means the United States of America.
	 
	(72)	 	“Work-In-Process” means Inventory that is not a product that is finished and approved by the
Borrowers in accordance with applicable Laws and the Borrowers’ normal business practices for
release and delivery to customers.
	 
	1.2	 	Accounting Terms and Determinations. Accounting terms not defined in this Agreement shall be
construed following GAAP, and calculations and determinations must be made following GAAP, in
each case, applied on a basis consistent with the most recent audited financial statements of
the Borrowers delivered to Asahi prior to the Closing Date; provided, however, that if
at any time any change in GAAP would affect the computation of any financial ratio or
financial requirement set forth in any Financing Document, and either the Borrowers or Asahi
shall so request, Asahi and the Borrowers shall negotiate in good faith to amend such ratio or
requirement to preserve the original intent thereof in light of such change in GAAP.
	 
	1.3	 	Other Definitional Provisions. References in this Agreement to “Articles”, “Sections”,
“Annexes”, “Exhibits” or “Schedules” shall be to Articles, Sections, Annexes, Exhibits or
Schedules of or to this Agreement unless otherwise specifically provided. Any term defined
herein may be used in the singular or plural. “Include”, “includes” and “including” shall be
deemed to be followed by “without limitation”. Except as otherwise specified or

12

 

	 	 	limited herein, references to any Person include the successors and assigns of such Person.
References “from” or “through” any date mean, unless otherwise specified, “from and
including” or “through and including”, respectively. References to any statute or act shall
include all related current regulations and all amendments and any successor statutes, acts
and regulations. References to any statute or act, without additional reference, shall be
deemed to refer to federal statutes and acts of the United States. References to any
agreement, instrument or document shall include all schedules, exhibits, annexes and other
attachments thereto. As used in this Agreement, the meaning of the term “material” or the
phrase “in all material respects” is intended to refer to an act, omission, violation or
condition which reflects or could reasonably be expected to result in a Material Adverse
Effect. References to capitalized terms that are not defined herein, but are defined in the
UCC, shall have the meanings given them in the UCC. All Riders attached hereto are hereby
incorporated herein by this reference and made a part hereof. Headings and captions used in
the Financing Documents (including the Exhibits, Schedules and Annexes hereto and thereto)
are included for convenience of reference only and shall not be given any substantive
effect.

ARTICLE 2 — TERM LOAN

	2.1	 	Term Loan.
	 
	(a)	 	Loan Amount. On the terms and subject to the conditions set forth herein, Asahi agrees to
make to NxStage Medical a term loan in an original principal amount equal Forty Million
Dollars ($40,000,000) (the “Term Loan”). NxStage Medical shall have no right to reborrow any
portion of the Term Loan that is repaid or prepaid from time to time. The Term Loan shall be
funded on the Closing Date, and principal shall be due and payable on the Maturity Date.
	 
	(b)	 	Repayment at Maturity; Optional Prepayments; Conversion.

	 	(A)	 	The Term Loan and any then unpaid interest thereon shall become due and
payable, and the Borrowers shall repay the Term Loan in full together with any then
unpaid interest thereon, on the Maturity Date in U.S. Dollars.
	 
	 	(B)	 	Asahi may require, by delivering a written notice to NxStage Medical no more
than ninety (90) days and no less than sixty (60) days prior to the Maturity Date, that
all of (but not only a portion of) the principal and interest on the Term Loan that is
unpaid as of the Maturity Date be converted into shares of NxStage Medical’s common
stock, with the number of shares to be determined based upon the average closing stock
price of NxStage Medical’s common stock, as reported on the Global NASDAQ Market during
the thirty (30) Business Days preceding the Maturity Date. Notwithstanding the
foregoing, Asahi’s election to be paid in NxStage Medical’s common stock shall under no
circumstance result in Asahi receiving more than 10% of the common shares of NxStage
Medical’s common stock outstanding as of the Maturity Date, provided that Asahi and
NxStage may mutually agree, each in its own sole discretion, to increase this 10%
limitation to an amount up to 20%.

13

 

	 	(C)	 	NxStage Medical may from time to time, with at least two (2) Business Days
prior delivery to Asahi of an appropriately payment notification, prepay the Term Loan
in whole or in part.

	(c)	 	Joint and Several Liability of the Borrowers. The obligations of the Borrowers to repay the
Term Loan shall be joint and several.
	 
	2.2	 	Interest and Interest Calculation.
	 
	(a)	 	Interest. From and following the Closing Date, the Term Loan shall bear interest at the rate
of eight percent (8%) per annum on the outstanding balance of the Term Loan, subject to any
default rate pursuant to Section 8.3. Fifty percent (50%) of all interest accruing on the
Term Loan shall be paid in arrears on the first (1st) day of each November and May, beginning
with November 1, 2009; with the remaining interest compounded at the rate of eight percent
(8%) annually, and due and payable on the Maturity Date. Interest on all other Obligations
shall be payable on demand.
	 
	(b)	 	Computation of Interest. All interest shall be calculated on the basis of a 360-day year for
the actual number of days elapsed. The date of funding of the Term Loan shall be included in
the calculation of interest. The date of payment of the Term Loan shall be excluded from the
calculation of interest.
	 
	2.3	 	Note. The Term Loan shall be evidenced by a note executed by the Borrowers (“Note”) in an
original principal amount equal to Forty Million Dollars ($40,000,000).
	 
	2.4	 	Maximum Interest. In no event shall the interest charged with respect to the Term Loan
exceed the maximum amount permitted under the laws of the Commonwealth of Massachusetts or of
any other applicable jurisdiction. Notwithstanding anything to the contrary herein or
elsewhere, if at any time the rate of interest payable with respect to the Term Loan (the
“Stated Rate”) would exceed the highest rate of interest permitted under any applicable law to
be charged (the “Maximum Lawful Rate”), then for so long as the Maximum Lawful Rate would be
so exceeded, the rate of interest payable shall be equal to the Maximum Lawful Rate; provided,
however, that if at any time thereafter the Stated Rate is less than the Maximum Lawful Rate,
the Borrowers shall, to the extent permitted by law, continue to pay interest at the Maximum
Lawful Rate until such time as the total interest received is equal to the total interest
which would have been received had the Stated Rate been (but for the operation of this
provision) the interest rate payable. Thereafter, the interest rate payable shall be the
Stated Rate unless and until the Stated Rate again would exceed the Maximum Lawful Rate, in
which event this provision shall again apply. In no event shall the total interest received
by the Asahi exceed the amount which it could lawfully have received had the interest been
calculated for the full term hereof at the Maximum Lawful Rate. If, notwithstanding the prior
sentence, the Asahi has received interest hereunder in excess of the Maximum Lawful Rate, such
excess amount shall be applied to the reduction of the principal balance of the Term Loan, and
if no such principal is then outstanding, such excess or part thereof remaining shall be paid
to the Borrowers. In computing interest payable with reference to the Maximum Lawful Rate
applicable to

14

 

	 	 	Asahi, such interest shall be calculated at a daily rate equal to the Maximum Lawful Rate
divided by the number of days in the year in which such calculation is made.
	 
	2.5	 	Taxes; Capital Adequacy. All payments of principal and interest on the Term Loan and all
other amounts payable hereunder shall be made free and clear of and without deduction for any
present or future income, excise, stamp, documentary, payroll, employment, property or
franchise taxes and other taxes, fees, duties, levies, assessments, withholdings or other
charges of any nature whatsoever (including interest and penalties thereon) imposed by any
taxing authority, excluding taxes imposed on or measured by Asahi’s net income by the
jurisdictions under which Asahi is organized or conducts business and excluding any taxes
arising as a consequence of Asahi not being a United States person (all non-excluded items
being called “Taxes”). (a) If any withholding or deduction from any payment to be made by any
Borrower hereunder is required in respect of any Taxes pursuant to any applicable Law, then
such Borrower will: (i) pay directly to the relevant authority the full amount required to be
so withheld or deducted; (ii) promptly forward to Asahi an official receipt or other
documentation reasonably satisfactory to Asahi evidencing such payment to such authority; and
(iii) pay to Asahi such additional amount or amounts as is necessary to ensure that the net
amount actually received by Asahi will equal the full amount Asahi would have received had no
such withholding or deduction been required. (b) If any Taxes are directly asserted against
Asahi with respect to any payment received by Asahi hereunder, Asahi may pay such Taxes and
NxStage Medical will promptly pay such additional amounts (including any penalty, interest or
expense) as is necessary in order that the net amount received by Asahi after the payment of
such Taxes (including any Taxes on such additional amount) shall equal the amount Asahi would
have received had such Taxes not been asserted so long as such amounts have accrued on or
after the day which is one hundred eighty (180) days prior to the date on which Asahi first
made written demand therefor. (c) If any withholding or deduction from any payment to be made
by any Borrower hereunder is required in respect of any taxes other than Taxes pursuant to any
applicable Law, then such Borrower will: (i) pay directly to the relevant authority the full
amount required to be so withheld or deducted; (ii) promptly forward to Asahi an official
receipt or other documentation reasonably satisfactory to Asahi evidencing such payment to
such authority; and (iii) pay to Asahi the payment less the full amount required to be so
withheld or deducted and paid to the relevant authority .

ARTICLE 3 — REPRESENTATIONS AND WARRANTIES

	 	 	To induce Asahi to enter into this Agreement and to make the Term Loan and other credit
accommodations contemplated hereby, each of the Borrowers hereby represents and warrants to
Asahi that:
	 
	3.1	 	Existence and Power. Each Borrower is a corporation duly organized, validly existing and in
good standing under the laws of the jurisdiction specified on Schedule 3.1 and no
other jurisdiction, has the same legal name as it appears in such Borrower’s Organizational
Documents and an organizational identification number (if any), in each case as specified on
Schedule 3.1, and has all powers and all Permits necessary in the operation of its
business as presently conducted, except where the failure to have such powers or Permits

15

 

	 	 	could not reasonably be expected to have a Material Adverse Effect. Each Borrower is
qualified to do business as a foreign entity in each jurisdiction in which it is required to
be so qualified, except where the failure to be so qualified could not reasonably be
expected to have a Material Adverse Effect. Except as set forth on Schedule 3.1,
each Borrower, over the five (5) year period preceding the Closing Date, (a) has not had any
name other than its current name, or (b) was not incorporated or organized under the laws of
any jurisdiction other than its current jurisdiction of incorporation or organization.
	 
	3.2	 	Organization and Governmental Authorization; No Contravention; Binding Effect. The
execution, delivery and performance by each Borrower of the Financing Documents to which it is
a party are within its powers, have been duly authorized by all necessary action pursuant to
its Organizational Documents, require no further action by or in respect of, or filing with,
any Governmental Authority and do not violate, conflict with or cause a breach or a default
under (a) any Law applicable to such Borrower or any of the Organizational Documents of such
Borrower, or (b) any agreement or instrument binding upon it, except for such violations,
conflicts, breaches or defaults as could not, with respect to this clause (b), reasonably be
expected to have a Material Adverse Effect. This Agreement and each of the other Financing
Documents to which each Borrower is a party constitutes a valid and binding agreement or
instrument of such Borrower, enforceable against such Borrower in accordance with its
respective terms, except as the enforceability thereof may be limited by bankruptcy,
insolvency or other similar laws relating to the enforcement of creditors’ rights generally
and by general equitable principles.
	 
	3.3	 	Capitalization. The authorized equity securities of each Borrower as of the Closing Date,
including all preemptive or other outstanding rights, options, warrants, conversion rights or
similar agreements or understandings, are as set forth on Schedule 3.3.
	 
	3.4	 	Financial Information; Solvency. All information delivered to Asahi and pertaining to the
financial condition of the Borrowers fairly presents in all material respects, when considered
together, the financial position of the Borrowers as of such date in conformity with GAAP (and
as to unaudited financial statements, subject to normal year-end adjustments and the absence
of footnote disclosures). As of March 31, 2009, there has been no material adverse change in
the business, operations, properties or financial condition of the Borrowers. The Borrowers,
considered as a whole, are Solvent.
	 
	3.5	 	Anti-Terrorism Laws. No Borrower, nor its Affiliates, nor any of their respective agents
acting or benefiting in any capacity in connection with the transactions contemplated by this
Agreement (i) is in violation of any Anti-Terrorism Law, (ii) engages in or conspires to
engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or
attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii) is
a Blocked Person. No Borrower, nor its Affiliates, nor agents acting or benefiting in any
capacity in connection with the transactions contemplated by this Agreement, (x) conducts any
business or engages in making or receiving any contribution of funds, goods or services to or
for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any
transaction relating to, any property or interest in property blocked pursuant to Executive
Order No. 13224, any similar executive order or other Anti-Terrorism Law.

16

 

	3.6	 	Interest Rate. The rate of interest paid under the Note and the method and manner of the
calculation thereof do not violate any usury or other law or applicable Laws, any of the
Organizational Documents or any of the Financing Documents.
	 
	3.7	 	Taxes. All material Federal, state and local tax returns, reports and statements (including
all such with respect to employee income tax withholding, social security and unemployment
taxes) required to be filed by or on behalf of each Borrower have been filed with the
appropriate Governmental Authorities in all jurisdictions in which such returns, reports and
statements are required to be filed for all periods for which returns were due and, except to
the extent subject to a Permitted Contest, all material taxes (including real property taxes,
employee income tax withholding, social security and unemployment taxes) and other charges
shown to be due and payable in respect thereof have been timely paid prior to the date on
which any fine, penalty, interest, late charge or loss may be added thereto for nonpayment
thereof (and, with respect to any employee income tax withholding, social security and
unemployment taxes not yet due, adequate provision for the payment thereof has been made).
Except to the extent subject to a Permitted Contest, all state and local sales and use Taxes
required to be paid by the Borrowers have been paid.
	 
	3.8	 	Litigation. There is no litigation or governmental proceeding pending or threatened in
writing against any Borrower which could reasonably be expected to have a Material Adverse
Effect or which challenges the validity and enforceability of the Financing Documents.
	 
	3.9	 	Ownership of Property. Each Borrower is the lawful owner of, has good and marketable title
to and is in lawful possession of, or has valid leasehold interests in, all material
properties and other assets (real or personal, tangible, intangible or mixed) purported or
reported to be owned or leased (as the case may be) by such Borrower, except where such
failure would not reasonably be expected to have a Material Adverse Effect.
	 
	3.10	 	No Default. No Event of Default, or to the Borrowers’ knowledge, Default, has occurred and
is continuing No Borrower is in breach or default under or with respect to any contract,
agreement, lease or other instrument to which it is a party or by which its property is bound
or affected, which breach or default could reasonably be expected to have a Material Adverse
Effect.
	 
	3.11	 	Labor Matters. As of the Closing Date, there are no strikes or other labor disputes pending
or, to the Borrowers’ knowledge, threatened against the Borrowers. Hours worked and payments
made to the employees of the Borrowers have not been in violation of the Fair Labor Standards
Act or any other applicable Law dealing with such matters other than violations that are both
unintentional and immaterial. All payments due from the Borrowers, or for which any claim may
be made against any of them, on account of wages and employee and retiree health and welfare
insurance and other benefits have been paid or accrued as a liability on their books, as the
case may be, except for the unintentional failure to make immaterial payments. The
consummation of the transactions contemplated by the Financing Documents will not give rise to
a right of termination or right of renegotiation on the part of any union under any collective
bargaining agreement to which it is a party or by which it is bound.

17

 

	3.12	 	Regulated Entities. No Borrower is an “investment company” or a company “controlled” by an
“investment company” or a “subsidiary” of an “investment company,” all within the meaning of
the Investment Company Act of 1940.
	 
	3.13	 	Margin Regulations. None of the proceeds from the Term Loan have been or will be used,
directly or indirectly, for the purpose of purchasing or carrying any “margin stock” (as
defined in Regulation U of the Federal Reserve Board), for the purpose of reducing or retiring
any indebtedness which was originally incurred to purchase or carry any “margin stock” or for
any other purpose which might cause the Term Loan to be considered a “purpose credit” within
the meaning of Regulation T, U or X of the Federal Reserve Board.
	 
	3.14	 	Compliance with Laws. The Borrowers are in compliance with the requirements of all
applicable Laws, except for such noncompliance which could not reasonably be expected to have
a Material Adverse Effect.
	 
	3.15	 	Compliance with ERISA.
	 
	(a)	 	Each ERISA Employee Benefit Plan (and the related trusts and funding agreements) complies in
form and in operation with, has been administered in compliance with, and the terms of each
ERISA Employee Benefit Plan satisfy, the applicable requirements of ERISA and the Code in all
material respects. Each ERISA Employee Benefit Plan which is intended to be qualified under
Section 401(a) of the Code is so qualified, and the United States Internal Revenue Service has
issued a favorable determination letter with respect to each such ERISA Employee Benefit Plan
which may be relied on currently. The Borrowers currently have no material liability for any
excise tax under any of Sections 4971 through 5000 of the Code.
	 
	(b)	 	During the thirty-six (36) month period prior to the Closing Date, (i) no steps have been
taken to terminate any Pension Plan and (ii) no contribution failure has occurred with respect
to any Pension Plan sufficient to give rise to a Lien under Section 302(f) of ERISA. No
condition exists or event or transaction has occurred with respect to any Pension Plan which
could result in the incurrence by the Borrowers of any material liability, fine or penalty.
The Borrowers have not incurred liability to the PBGC (other than for current premiums) with
respect to any employee Pension Plan. All contributions (if any) have been made on a timely
basis to any Multiemployer Plan that are required to be made by the Borrowers or any other
member of the Controlled Group under the terms of the plan or of any collective bargaining
agreement or by applicable Law; the Borrowers nor any member of the Controlled Group has
withdrawn or partially withdrawn from any Multiemployer Plan, incurred any withdrawal
liability with respect to any such plan or received notice of any claim or demand for
withdrawal liability or partial withdrawal liability from any such plan, and no condition has
occurred which, if continued, could result in a withdrawal or partial withdrawal from any such
plan, and the Borrowers nor any member of the Controlled Group has received any notice that
any Multiemployer Plan is in reorganization, that increased contributions may be required to
avoid a reduction in plan benefits or the imposition of any excise tax, that any such plan is
or has been funded at a rate less than that required under Section 412 of the Code, that any
such plan is or may be terminated, or that any such plan is or may become insolvent. The
Borrowers are not participants in any Multiemployer Plan.

18

 

	3.16	 	Compliance with Environmental Requirements; No Hazardous Materials.
	 
	(a)	 	No notice, notification, demand, request for information, citation, summons, complaint or
order has been issued, no complaint has been filed, no penalty has been assessed and no
investigation or review is pending, or to the Borrowers’ knowledge, threatened to or against
the Borrowers real or personal property (now owned or leased or previously owned or leased) by
any Governmental Authority or other Person with respect to any (i) alleged violation by the
Borrowers of any Environmental Law, (ii) alleged failure by the Borrowers to have any Permits
under any Environmental Law or relating to any Hazardous Materials required in connection with
the conduct of its business or to comply with the terms and conditions thereof, (iii)
generation, treatment, storage, recycling, transportation or disposal of any Hazardous
Materials, or (iv) release of Hazardous Materials in each case where the notice, notification,
demand, request for information, citation, summons, complaint or order could be reasonably
expected to have a Materially Adverse Effect;
	 
	(b)	 	No property now owned or leased by the Borrowers and, to the knowledge of each Borrower, no
such property previously owned or leased by the Borrowers, on which the Borrowers have
generated, stored or disposed of or to which the Borrowers have, directly or indirectly,
transported or arranged for the transportation of any Hazardous Materials, is listed or, to
the Borrowers’ knowledge, proposed for listing, on the National Priorities List promulgated
pursuant to CERCLA, or CERCLIS (as defined in CERCLA) or any similar state list or is the
subject of federal, state or local enforcement actions or other investigations which may lead
to claims against the Borrowers for clean-up costs, remedial work, damage to natural resources
or personal injury claims, including, without limitation, claims under CERCLA.

ARTICLE 4 — AFFIRMATIVE COVENANTS

	 	 	The Borrowers agree that, so long as any principal or interest on account of the Term Loan
remains outstanding:
	 
	4.1	 	Financial Statements and Other Reports. The Borrowers will deliver to Asahi: (1) as soon as
available, but no later than the period then allowed for fiscal quarterly reporting to the SEC
per SEC Regulation S-K, a company prepared consolidated balance sheet, cash flow and income
statement covering the Borrowers’ consolidated operations during the period, prepared under
GAAP, consistently applied, certified by a Responsible Officer and in a form reasonably
acceptable to Asahi; (2) as soon as available, but no later than the period then allowed for
fiscal annual reporting to the SEC per SEC Regulation S-K after the last day of the Borrowers’
fiscal year, audited consolidated financial statements prepared under GAAP, consistently
applied, together with an opinion on the financial statements from Ernst & Young or another
independent certified public accounting firm acceptable to Asahi in its reasonable discretion;
(3) within five (5) days of delivery or filing thereof, copies of all statements, reports and
notices made available to the Borrowers’ security holders and copies of all reports and other
filings made by the Borrowers with any stock exchange on which any securities of the Borrowers
are traded and/or the SEC; and (4) within five (5) days of NxStage Medical receiving approval
from its Board of Directors thereof, copies of any Board approved budgets or operating plans
for NxStage Medical.

19

 

	 	 	Documents required to be delivered pursuant to this Section 4.1 (to the extent any such
documents are included in materials otherwise filed with the SEC) may be delivered
electronically and if so delivered, shall be deemed to have been delivered on the date on
which the Borrowers post such documents, or provide a link thereto on NxStage Medical’s
website on the Internet at NxStage Medical’s website address of www.nxstage.com (or such
other website address as the Borrowers may provide to Asahi in writing from time to time);
provided, that to the extent Asahi is otherwise unable to receive any such electronically
delivered documents, the Borrowers shall, upon request by Asahi, deliver paper copies of
such documents to Asahi until a written request to cease delivering paper copies is given by
Asahi.
	 
	4.2	 	Payment and Performance of Liabilities and Obligations. The Borrowers will: (a) pay and
discharge at or prior to maturity, all of its respective obligations and liabilities,
including all tax liabilities of all kind, except for such obligations and/or liabilities (i)
that may be the subject of a Permitted Contest, or (ii) the nonpayment or nondischarge of
which could not reasonably be expected to have a Material Adverse Effect; (b) maintain in
accordance with GAAP, appropriate reserves for the accrual of all of their respective
obligations and liabilities, including all tax liabilities of all kind; and (c) not breach or
permit any Subsidiary to breach, or permit to exist any default under, the terms of any
Material Contract or any other lease, commitment, contract, instrument or obligation to which
it is a party, or by which its properties or assets are bound, except for such breaches or
defaults which could not reasonably be expected to have a Material Adverse Effect.
	 
	4.3	 	Maintenance of Existence; Property; Insurance.
	 
	(a)	 	Each of the Borrowers will preserve, renew and keep in full force and effect and in good
standing (i) its existence and (ii) its rights, privileges and franchises necessary in the
normal conduct of business.
	 
	(b)	 	Each of the Borrowers will at all times be the lawful owner of, have good and marketable
title to and be in lawful possession of, or have valid leasehold interests in, all material
properties and other assets (real or personal, tangible, intangible or mixed) purported or
reported to be owned or leased (as the case may be) by such Person that are necessary in the
normal course of business. Each of the Borrowers will keep all material property useful and
necessary in its business in good working order and condition, ordinary wear and tear
excepted.
	 
	(c)	 	NxStage Medical will, and will cause each of the Borrowers to, maintain (i) all insurance
described on Schedule 4.3, upon the terms and with the coverages and rights in favor
of Asahi as described in Schedule 4.3, and (ii) such other insurance coverage in such amounts
and with respect to such risks as may be available at commercially reasonable rates and as may
be customary in such Borrower’s business and industry and that Asahi may reasonably from time
to time request, provided, however, that, in no event shall such insurance be in amounts or
with coverage less than, or with carriers with qualifications materially inferior to, any of
the insurance or carriers in existence as of the Closing Date. All such insurance shall be
provided by insurers having an A.M. Best policyholders rating reasonably acceptable to Asahi.
The Borrowers will deliver to Asahi (i) at least 30 days prior to expiration of any policy of
insurance, evidence of renewal of such insurance upon

20

 

	 	 	the terms and conditions herein required, (ii) upon the request of Asahi from time to time
full information as to the insurance carried, and (iii) within five (5) days of receipt of
notice from any insurer, a copy of any notice of cancellation, nonrenewal or material change
in coverage from that existing on the date of this Agreement, and (iv) forthwith, notice of
any cancellation or nonrenewal of coverage by the Borrowers. In the event any Borrower (i)
fails to maintain the insurance coverage required by this Agreement, or (ii) fails to
provide Asahi with evidence of the insurance coverage required by this Agreement and such
failure to provide evidence continues for five (5) Business Days, Asahi may (but shall have
no obligation to) purchase insurance at the Borrower’s expense to protect Asahi’s interests
in the Collateral and to protect Asahi from liability claims relating to the Borrowers’
operations, and the costs and expenses of Asahi in obtaining and paying the premiums on any
such insurance shall constitute part of the Obligations for which the Borrowers are liable
hereunder and which are secured by the Collateral. In the event that the Borrowers shall at
any time receive any insurance proceeds under any property or casualty insurance maintained
by the Borrowers in connection with any casualty event involving the Collateral (other than
any Field Equipment or any product inventories), if the Borrowers does not use such
insurance proceeds to replace or repair any affected property, NxStage Medical shall turn
over and deliver to Asahi any and all such proceeds in the form received together with any
necessary endorsement thereto.
	 
	4.4	 	Compliance with Laws and Contracts. Each of the Borrowers will comply with the requirements
of all applicable Laws and all Material Contracts, except to the extent that failure to so
comply could not reasonably be expected to have a Material Adverse Effect. The closing on and
consummation of the transactions contemplated by the Financing Documents will not give rise to
a right of termination under any Material Contract in favor of any party to such Material
Contract.
	 
	4.5	 	Inspection of Property, Books and Records. The Borrowers will permit, at the sole cost of
the Borrowers (subject to Section 10.11(c))), Asahi to examine and make abstracts or copies
from any of their respective books and records, to visit and inspect Borrowers’ facilities, to
conduct a collateral audit and analysis of their respective operations and the Collateral, and
to discuss their respective finances and accounts with their respective officers, provided
that such examinations, visits, inspections, audits, and discussions shall be limited to
matters directly affecting the repayment of the Term Loan and shall be conducted at times and
in manners reasonably acceptable to the Borrowers and Asahi (it being understood that no
notice shall be required for Asahi to visit the Borrowers’ facilities during the existence and
continuance of any Event of Default) . Notwithstanding any other provision of this Agreement
to the contrary, Asahi shall not be entitled to review or receive any information that could
reasonably expose the Borrowers or Asahi to any antitrust or similar law or that the Borrowers
reasonably determine would provide Asahi with a competitive advantage over NxStage.
	 
	4.6	 	Use of Proceeds. No portion of the proceeds of the Term Loan will be used for family,
personal, agricultural or household use.
	 
	4.7	 	Notices of Certain Events.

21

 

	 	 	The Borrowers will give prompt written notice to Asahi (a) of any litigation or governmental
proceedings pending or threatened (in writing) against any Borrower which would reasonably
be expected to have a Material Adverse Effect with respect to the Borrowers or which
challenges the validity or enforceability of any Financing Document, (b) upon any Borrower
becoming aware of the existence of any Default or Event of Default, (c) if any Borrower is
in breach or default under or with respect to any Material Contract or any other contract,
agreement, lease or other instrument to which it is a party or by which its property is
bound or affected, which breach or default could reasonably be expected to have a Material
Adverse Effect, (d) any strikes or other labor disputes pending against any Borrower, and
(e) if any Borrower has actual knowledge of any infringement or claim of infringement by any
other Person with respect to any Intellectual Property rights of any Borrower that could
reasonably be expected to have a Material Adverse Effect, or if there is any written claim
by any other Person that any Borrower in the conduct of its business is infringing on the
Intellectual Property Rights of others that could reasonably be expected to have a Material
Adverse Effect. The Borrowers represents and warrants that Schedule 4.7 sets forth
a complete list of all matters existing as of the Closing Date for which notice would be
required under this Section 4.7 and all litigation or governmental proceedings pending or
threatened (in writing) against the Borrowers as of the Closing Date. Without limiting the
generality of the foregoing, the Borrowers will give prompt written notice to Asahi (f) of
the issuance of any notice, notification, demand, request for information, citation,
summons, complaint or order, filing of any complaint, assessment of any penalty or
initiation or initiation or threat to initiate any investigation or review, in each such
case whether by any Governmental Authority or other Person, with respect to any (i) alleged
violation by the Borrowers of any applicable Environmental Law, (ii) alleged failure by the
Borrowers to have any Permits relating to or granted under any applicable Environmental Law
required in connection with the conduct of its business or to comply with the terms and
conditions thereof, except where the failure to have such Permits relating to or granted
under any Environmental Law could not reasonably be expected to have a Material Adverse
Effect, (iii) any generation, treatment, storage, recycling, transportation or disposal of
any Hazardous Materials by the Borrowers, or (iv) release of Hazardous Materials by the
Borrowers; (g) if any property now owned or leased by NxStage or, to the knowledge of the
Borrowers, any property previously owned or leased by the Borrowers, to which the Borrowers
has, directly or indirectly, transported or arranged for the transportation of any Hazardous
Materials, becomes listed or, to the Borrower’s knowledge, becomes proposed for listing, on
the National Priorities List promulgated pursuant to CERCLA, or CERCLIS (as defined in
CERCLA) or any similar state list or becomes the subject of Federal, state or local
enforcement actions or, to the knowledge of the Borrowers, other investigations which may
lead to claims against the Borrowers for clean-up costs, remedial work, damage to natural
resources or personal injury claims, including, without limitation, claims under CERCLA.
For purposes of this Section 4.7(g), the Borrowers shall be deemed to include any business
or business entity (including a corporation) that is, in whole or in part, a predecessor of
the Borrowers to the extent the Borrowers could reasonably be expected to incur liability in
connection therewith.
	 
	4.8	 	Intellectual Property. Each of the Borrowers owns and shall own, is and will be licensed to
use or otherwise has and will have the right to use, all Intellectual Property that is

22

 

	 	 	necessary to its business and operations. Each of the Borrowers shall, to the extent it
determines, in the exercise of its reasonable business judgment, that it is prudent to do
the following: (a) protect, defend and maintain the validity and enforceability of its
Intellectual Property; and (b) not allow any Intellectual Property necessary to such
Borrower’s business to be abandoned, forfeited or dedicated to the public without Asahi’s
written consent. Upon Asahi’s request, NxStage Medical agrees to provide Asahi a list of
all issued patents and published patent applications owned by NxStage Medical or any of its
Subsidiaries.
	 
	4.9	 	Hazardous Materials; Remediation. If any release or disposal of Hazardous Materials shall
occur or shall have occurred on any real property or any other assets of any Borrower, the
Borrowers will cause, or direct the applicable Subsidiary to cause, the prompt containment and
removal of such Hazardous Materials and the remediation of such real property or other assets
as is necessary to comply with all applicable Environmental Laws and to preserve the value of
such real property or other assets unless failure to do so would not have a Materially Adverse
Effect. Without limiting the generality of the foregoing, the Borrowers shall materially
comply with each applicable Environmental Law requiring the performance at any real property
by the Borrowers of activities in response to the release or threatened release of a Hazardous
Material.
	 
	4.10	 	The Borrower shall from time to time provide to Asahi such information in regards to this
Agreement as Asahi may reasonably request, whether under Section 5.8 or otherwise, as
specified under this Agreement.

ARTICLE 5 — NEGATIVE COVENANTS

	 	 	Each of the Borrowers agrees that, so long as principal or interest on account of the Term
Loan remains outstanding:
	 
	5.1	 	Debt; Contingent Obligations. The Borrowers will not, directly or indirectly, create, incur,
assume, guarantee or otherwise become or remain directly or indirectly liable with respect to,
any Debt, except for Permitted Indebtedness. The Borrowers will not, directly or indirectly,
create, assume, incur or suffer to exist any Contingent Obligations, except for Permitted
Contingent Obligations.
	 
	5.2	 	Liens. The Borrowers will not, directly or indirectly, create, assume or suffer to exist any
Lien on any asset now owned or hereafter acquired by it, except for Permitted Liens.
	 
	5.3	 	Restricted Distributions. The Borrowers will not, directly or indirectly, declare, order,
pay, make or set apart any sum for any Restricted Distribution, except for Permitted
Distributions.
	 
	5.4	 	Consolidations, Mergers and Sales of Assets. No Borrower will, directly or indirectly (a)
consolidate or merge or amalgamate with or into any other Person, other than pursuant to a
Permitted Acquisition, or (b) consummate any Asset Dispositions other than Permitted Asset
Dispositions.
	 
	5.5	 	Purchase of Assets, Investments; New Subsidiaries.

23

 

	 	 	No Borrower will, directly or indirectly, without the prior written
consent of Asahi, (a) acquire or enter into any agreement to acquire
any assets other than in the Ordinary Course of Business or Permitted
Acquisitions; (b) engage or enter into any agreement to engage in any
joint venture or partnership with any other Person except in the
Ordinary Course of Business if not otherwise prohibited hereunder; or
(c) form, acquire or own or enter into any agreement to form, acquire
or own any Investment in any Person, including any new Subsidiary,
other than pursuant to Permitted Investments or Permitted Acquisitions
(in which case (i) such new Subsidiary shall, if it is a U.S. entity,
become a Borrower hereunder by executing an accession hereto and to
any other applicable Financing Documents, (ii) such new Subsidiary
shall, if it is a non-U.S. entity, become a Guarantor hereunder by
executing an accession hereto and to any other applicable Financing
Documents, and (iii) the owner of the equity in such Subsidiary shall
pledge such equity to Asahi as Collateral.
	 
	5.6	 	Conduct of Business. No Borrower will, directly or indirectly, engage in any line of
business other than those businesses engaged in on the Closing Date and businesses reasonably
related thereto.
	 
	5.7	 	Deposit Accounts and Securities Accounts. No Borrower will, directly or indirectly,
establish any new Deposit Account or Securities Account without prior written notice to Asahi
except for (i) accounts used exclusively for payroll or other employment or tax related
payments, (ii) accounts holding cash collateral for letters of credit contemplated by the
definition of Permitted Liens, and (iii) other accounts holding no more than $1,000,000 in the
aggregate, of cash, Investment Property, Securities or other assets.
	 
	5.8	 	Compliance with Anti-Terrorism Laws. Asahi hereby notifies the Borrowers that pursuant to
the requirements of Anti-Terrorism Laws, Asahi may be required from time to time to obtain,
verify and record certain information and documentation that identifies the Borrowers and its
principals, which information includes the name and address of Borrower and its principals and
such other information that will allow Asahi to identify such party in accordance with
Anti-Terrorism Laws. The Borrowers will not knowingly enter into any Material Contracts with
any Blocked Person or any Person listed on the OFAC Lists. The Borrowers shall immediately
notify Asahi if any Borrower has knowledge that any Borrower becomes a Blocked Person or
becomes listed on the OFAC Lists or (a) is convicted on, (b) pleads nolo contendere to, (c) is
indicted on, or (d) is arraigned and held over on charges involving money laundering or
predicate crimes to money laundering. The Borrowers will not, directly or indirectly, (i)
conduct any business or engage in any transaction or dealing with any Blocked Person,
including, without limitation, the making or receiving of any contribution of funds, goods or
services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any
transaction relating to, any property or interests in property blocked pursuant to Executive
Order No. 13224, any similar executive order or other Anti-Terrorism Law, or (iii) engage in
or conspire to engage in any transaction that evades or avoids, or has the purpose of evading
or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No.
13224 or other Anti-Terrorism Law.
	 
	5.9	 	Specified Contracts. Medisystems will not amend, modify, waive, or terminate any material
term of the DSU License Agreement.

24

 

ARTICLE 6 — CONDITIONS

	6.1	 	Conditions to Effective of this Agreement. This Agreement shall become effective on the
Effective Date, subject to the execution hereof by all of the Parties.
	 
	6.2	 	Conditions to Closing. The obligation of Asahi to make the Term Loan shall be subject to the
satisfaction of the “break of escrow” conditions set forth in the Escrow Agreement.

ARTICLE 7 — SECURITY AGREEMENT

	7.1	 	Generally. As security for the payment and performance of the Obligations, and without
limiting any other grant of a Lien and security interest in any Security Document, each
Borrower hereby grants and pledges to Asahi, for the benefit of Asahi, a continuing first
priority and sole Lien on and security interest in, upon, and to the personal property set
forth on Schedule 7.1 attached hereto and made a part hereof.
	 
	7.2	 	Representations and Warranties and Covenants Relating to Collateral.
	 
	(a)	 	The Borrowers shall not take any of the following actions or make any of the following
changes unless the Borrowers have given at least thirty (30) days prior written notice to
Asahi of the Borrowers’ intention to take any such action and have executed any and all
documents, instruments and agreements and taken any other actions which Asahi may reasonably
request after receiving such written notice in order to protect and preserve the Liens, rights
and remedies of Asahi with respect to the Collateral: (i) change the legal name or
organizational identification number of any Borrower as it appears in official filings in the
jurisdiction of its organization, (ii) change the jurisdiction of incorporation or formation
of any Borrower or allow any Borrower to designate any jurisdiction as an additional
jurisdiction of incorporation for such Borrower, or change the type of entity that it is, or
(iii) change its chief executive office, principal place of business, or the location of its
records concerning the Collateral or move any Collateral to or place any Collateral on any
location that is not then listed on the Schedules and/or establish any business location at
any location that is not then listed on the Schedules.
	 
	(b)	 	No Collateral shall at any time be in the possession or control of any warehouse, consignee,
bailee or any of NxStage’s agents or processors without prior written notice to Asahi and the
receipt by Asahi, if Asahi has so requested, of warehouse receipts, consignment agreements or
bailee lien waivers (as applicable) reasonably satisfactory to Asahi prior to the commencement
of such possession or control. NxStage shall, upon the request of Asahi, notify any such
warehouse, consignee, bailee, agent or processor of the security interests and Liens in favor
of Asahi created pursuant to this Agreement and the Security Documents, instruct such Person
to hold all such Collateral for Asahi’s account subject to Asahi’s instructions (or, in the
case of any Permitted Lien on such Collateral, subject to the instructions of the holder of
such Permitted Lien in accordance with any intercreditor agreement or subordination agreement
executed by Asahi and the holder of such Permitted Lien) and shall obtain an acknowledgement
from such Person that such Person holds the Collateral for Asahi’s benefit (and, in the case
of any Permitted Lien on such Collateral, for

25

 

	 	 	the benefit of the holder of such Permitted Lien in accordance with any intercreditor
agreement or subordination agreement executed by Asahi and the holder of such Permitted
Lien).
	 
	(c)	 	Each Borrower hereby authorizes Asahi to file without the signature of such Borrower one or
more UCC financing statements relating to liens on personal property relating to all or any
part of the Collateral, which financing statements may list Asahi as the “secured party” and
such Borrower as the “debtor” and which describe and indicate the collateral covered thereby
as all or any part of the Collateral under the Financing Documents, in such jurisdictions as
Asahi from time to time determines are appropriate, and to file without the signature of such
Borrower any continuations of or corrective amendments to any such financing statements, in
any such case in order for Asahi to perfect, preserve or protect the Liens, rights and
remedies of Asahi and Lenders with respect to the Collateral.
	 
	(d)	 	The Borrowers shall furnish to Asahi from time to time any statements and schedules further
identifying or describing the Collateral and any other information, reports or evidence
concerning the Collateral as Asahi may reasonably request from time to time.
	 
	(e)	 	Upon request of Asahi, the Borrowers shall promptly deliver to Asahi any and all certificates
of title, applications for title or similar evidence of ownership of all tangible property for
which certificates of title are issued.
	 
	(f)	 	Upon request of Asahi, the Borrowers shall promptly deliver to Asahi any and all certificates
of title, applications for title or similar evidence of ownership of all such tangible
Personal Property and shall cause Asahi to be named as lienholder on any such certificates of
title or other evidence of ownership. The Borrowers shall not permit any such tangible
Personal Property to become Fixtures to real estate unless such real estate is subject to a
Lien in favor of Asahi.
	 
	7.3	 	UCC Remedies.
	 
	(a)	 	Upon the occurrence of and during the continuance of an Event of Default under this Agreement
or the other Financing Documents, Asahi may commence the exercise of rights and remedies
against the Borrowers and the Collateral for its benefit. Asahi shall so commence such
exercise of rights and remedies, in addition to all other rights, options, and remedies
granted to Asahi under this Agreement or at law or in equity, may exercise, either directly or
through one or more assignees or designees, all rights and remedies granted to it under all
Financing Documents and under the UCC in effect in the applicable jurisdiction(s) and under
any other applicable law; including, without limitation:

	 	(i)	 	The right to take possession of, send notices regarding, and collect directly
the Collateral, with or without judicial process;
	 
	 	(ii)	 	The right to (by its own means or with judicial assistance) enter any of the
Borrowers’ premises and take possession of the Collateral, or render it unusable, or to
render it usable or saleable, or dispose of the Collateral on such premises in
compliance with subsection (iii) below and to take possession of the Borrowers’
original books and records, to obtain access to the Borrowers’ data processing
equipment, computer hardware and software relating to the Collateral and to use all

26

 

	 	 	 	of the foregoing and the information contained therein in any manner Asahi deems
appropriate, without any liability for rent, storage, utilities, or other sums, and
the Borrowers shall not resist or interfere with such action (if the Borrowers’
books and records are prepared or maintained by an accounting service, contractor or
other third party agent, the Borrowers hereby irrevocably authorize such service,
contractor or other agent, upon notice by Asahi to such Person that an Event of
Default has occurred and is continuing, to deliver to Asahi or its designees such
books and records, and to follow Asahi’s instructions with respect to further
services to be rendered); and
	 
	 	(iii)	 	The right to require the Borrowers at the Borrowers’ expense to assemble all
or any part of the Collateral and make it available to Asahi at any place designated by
Asahi.

	(b)	 	The Borrowers agree that a notice received by it at least ten (10) days before the time of
any intended public sale, or the time after which any private sale or other disposition of the
Collateral is to be made, shall be deemed to be reasonable notice of such sale or other
disposition. If permitted by applicable law, any perishable Collateral which threatens to
speedily decline in value or which is sold on a recognized market may be sold immediately by
Asahi without prior notice to the Borrowers. At any sale or disposition of Collateral in an
exercise of rights and remedies, Asahi may (to the extent permitted by applicable law)
purchase all or any part of the Collateral, free from any right of redemption by the
Borrowers, which right is hereby waived and released. Each of the Borrowers covenants and
agrees not to interfere with or impose any obstacle to Asahi’s exercise of its rights and
remedies with respect to the Collateral. Asahi shall have no obligation to clean-up or
otherwise prepare the Collateral for sale. Asahi may comply with any applicable state or
federal law requirements in connection with a disposition of the Collateral and compliance
will not be considered to adversely affect the commercial reasonableness of any sale of the
Collateral. Asahi may sell the Collateral without giving any warranties as to the Collateral.
Asahi may specifically disclaim any warranties of title or the like. This procedure will not
be considered to adversely affect the commercial reasonableness of any sale of the Collateral.
If Asahi sells any of the Collateral upon credit, the Borrowers will be credited only with
payments actually made by the purchaser, received by Asahi and applied to the indebtedness of
the purchaser. In the event the purchaser fails to pay for the Collateral, Asahi may resell
the Collateral in an exercise of rights and remedies and the Borrowers shall be credited with
the proceeds of the sale. The Borrowers shall remain liable for any deficiency if the proceeds
of any such sale or disposition of the Collateral are insufficient to pay all Obligations.
	 
	(c)	 	Without restricting the generality of the foregoing and for the purposes aforesaid, each of
the Borrowers hereby appoints and constitutes Asahi its lawful attorney-in-fact with full
power of substitution in the Collateral, to pay, settle or compromise all existing bills and
claims, which may be Liens or security interests, or to avoid such bills and claims becoming
Liens against the Collateral; to execute all applications and certificates in the name of such
Borrower and to prosecute and defend all actions or proceedings in connection with the
Collateral; and to do any and every act which such Borrower might do in its own behalf; it
being understood and agreed that this power of attorney shall be a power coupled with an
interest and cannot be revoked.

27

 

	(d)	 	Asahi is hereby granted an irrevocable, non-exclusive, royalty-free license or other right to
use, without charge, NxStage’s labels, mask works, rights of use of any name, any other
Intellectual Property and advertising matter, and any similar property as it pertains to the
Collateral upon the occurance and during the continuance of an Event of Default, in completing
production of, advertising for sale, and selling any Collateral and, in connection with
Asahi’s exercise of its rights under this Article, NxStage’s rights under all licenses and all
franchise agreements inure to Asahi’s benefit.

ARTICLE 8 — EVENTS OF DEFAULT

	8.1	 	Events of Default.
	 
	 	 	For purposes of the Financing Documents, the occurrence of any of the following conditions
and/or events, whether voluntary or involuntary, by operation of law or otherwise, shall
constitute an “Event of Default”:
	 
	(a)	 	the Borrowers shall fail to pay when due any principal, interest, premium or fee under any
Financing Document or any other amount payable under any Financing Document, in each case
within three (3) Business Days after any such principal, interest or fee becomes due;
	 
	(b)	 	the Borrowers default in the performance of or compliance with any term contained in this
Agreement or in any other Financing Document and such default is not remedied by the Borrowers
or waived by Asahi within thirty (30) days after the earlier of the date on which (x) the
Borrowers have actual knowledge of such default, or (y) the Borrowers receive notice thereof
from Asahi;
	 
	(c)	 	any representation, warranty, certification or statement made by the Borrowers in any
Financing Document or in any certificate, financial statement or other document delivered
pursuant to any Financing Document is incorrect in any respect (or in any material respect if
such representation, warranty, certification or statement is not by its terms already
qualified as to materiality) when made (or deemed made);
	 
	(d)	 	any Borrower shall commence a voluntary case or other proceeding seeking liquidation,
reorganization or other relief with respect to itself or its debts under any bankruptcy,
insolvency or other similar law now or hereafter in effect or seeking the appointment of a
trustee, receiver, liquidator, custodian or other similar official of it or any substantial
part of its property, or shall consent to any such relief or to the appointment of or taking
possession by any such official in an involuntary case or other proceeding commenced against
it, or shall make a general assignment for the benefit of creditors, or shall fail generally
to pay its obligations to any other borrowing or guarantee as they become due, or shall take
any corporate action to authorize any of the foregoing;
	 
	(e)	 	an involuntary case or other proceeding shall be commenced against any Borrower seeking
liquidation, reorganization or other relief with respect to it or its debts under any
bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the
appointment of a trustee, receiver, liquidator, custodian or other similar official of it or
any substantial part of its property, and such involuntary case or other proceeding shall
remain

28

 

	 	 	undismissed and unstayed for a period of forty-five (45) days; or an order for relief shall
be entered against any Borrower under applicable federal bankruptcy, insolvency or other
similar law in respect of (i) bankruptcy, liquidation, winding-up, dissolution or suspension
of general operations, (ii) composition, rescheduling, reorganization, arrangement or
readjustment of, or other relief from, or stay of proceedings to enforce, some or all of the
debts or obligations.
	 
	(f)	 	one or more judgments or orders for the payment of money (not paid or fully covered by
insurance maintained in accordance with the requirements of this Agreement and as to which the
relevant insurance company has acknowledged coverage) aggregating in excess of $1,000,000
shall be rendered against any or all of the Borrowers and either (i) enforcement proceedings
shall have been commenced by any creditor upon any such judgments or orders, or (ii) there
shall be any period of twenty (20) consecutive days during which a stay of enforcement of any
such judgments or orders, by reason of a pending appeal, bond or otherwise, shall not be in
effect; or
	 
	(g)	 	any Lien created by any of the Security Documents shall at any time fail to constitute a
valid and perfected Lien on all of the Collateral purported to be encumbered thereby (unless
otherwise expressly permitted hereunder or affecting only an immaterial portion of the
Collateral), subject to no prior or equal Lien except Permitted Liens, or any of the Borrowers
shall so assert.
	 
	(h)	 	the occurance of any fact, event or circumstance that has resulted in a Material Adverse
Effect. All cure periods provided for in this Section 8.1 shall run concurrently with any
cure period provided for in any applicable Financing Documents under which the default
occurred.
	 
	8.2	 	Acceleration and Suspension. Upon the occurrence and during the continuance of an Event of
Default, Asahi may, by notice to the Borrowers, declare the Obligations to be, and the
Obligations shall thereupon become, immediately due and payable without presentment, demand,
protest or other notice of any kind, all of which are hereby waived by the Borrowers, and the
Borrowers will pay the same; provided, however, that in the case of any of the Events of
Default specified in Section 8.1 (d) or 8.1 (e) above, with any notice to any Borrower or any
other act by Asahi, all of the Obligations shall become immediately and automatically due and
payable without presentment, demand, protest or other notice of any kind, all of which are
hereby waived by the Borrowers, and the Borrowers will pay the same. Asahi may require, by
delivering a written notice to the Borrowers following any acceleration pursuant to this
Section 8.2, that all of (but not only a portion of) the Term Loan unpaid as of such date be
converted into shares of NxStage Medical’s common stock, with the number of shares to be
determined based upon the average closing stock price of NxStage Medical’s common stock, as
reported on the Global NASDAQ Market during the thirty (30) Business Days preceding the date
of such notice. Notwithstanding the foregoing, Asahi’s election to be paid in NxStage
Medical’s common stock shall under no circumstance result in Asahi receiving more than 10% of
the common shares of NxStage Medical’s common stock outstanding as of the Maturity Date,
provided that Asahi and NxStage may mutually agree, each in its own sole discretion, to
increase this 10% limitation to an amount up to 20%.

29

 

	8.3	 	Default Rate of Interest. After the occurrence of an Event of Default and for so long as it
continues, the Term Loans and other Obligations then outstanding shall automatically bear
interest at the rate of thirteen percent (13%) per annum rather than, and in lieu of, the rate
of eight percent (8%) per annum set forth in Section 2.2
	 
	8.4	 	Setoff Rights. During the continuance of any Event of Default, Asahi is hereby authorized by
the Borrowers at any time or from time to time, with reasonably prompt subsequent notice to
the Borrowers (any prior or contemporaneous notice being hereby expressly waived) to set off
and to appropriate and to apply any and all (a) balances held by such Asahi or any of such
Asahi ’s Affiliates at any of its offices for the account of the Borrowers (regardless of
whether such balances are then due to the Borrowers), and (b) other property at any time held
or owing by Asahi to or for the credit or for the account of the Borrowers, against and on
account of any of the Obligations. The Borrowers agree, to the fullest extent permitted by
law, that Asahi and any of Asahi’s Affiliates may exercise its right to set off with respect
to the Obligations as provided in this Section.
	 
	8.5.	 	Waivers and Remedies.
	 
	(a)	 	Each of the Borrowers, for itself and all its successors and assigns, (i) agrees that its
liability shall not be in any manner affected by any acquiescence in non-compliance,
indulgence, extension of time, renewal, waiver, or modification made, granted or consented to
by Asahi; (ii) consents to any indulgences and all extensions of time, renewals, waivers, or
modifications that may be granted by Asahi with respect to the payment or other provisions of
the Financing Documents, and to any substitution, exchange or release of the Collateral, or
any part thereof, with or without substitution, and agrees to the addition or release of any
endorsers, guarantors, or sureties, or whether primarily or secondarily liable, without notice
to the Borrowers and without affecting its liability hereunder; (iii) agrees that its
liability shall be unconditional and without regard to the liability of Asahi for any tax on
the indebtedness; and (iv) to the fullest extent permitted by law, expressly waives the
benefit of any statute or rule of law or equity now provided, or which may hereafter be
provided, which would produce a result contrary to or in conflict with the foregoing.
	 
	(b)	 	Any delay or forbearance by Asahi in exercising any right or remedy under any of the
Financing Documents, or otherwise afforded by applicable law, including any failure to
accelerate the Maturity Date of the Term Loan, shall not be a waiver of or preclude the
exercise of any right or remedy nor shall it serve as a reinstatement of the Term Loan or a
waiver of such right of acceleration or the right to insist upon strict compliance of the
terms of the Financing Documents. Asahi’s acceptance of payment of any sum secured by any of
the Financing Documents after the due date of such payment shall not be a waiver of Asahi’s
right to either require prompt payment when due of all other sums so secured or to declare a
default for failure to make prompt payment.
	 
	(c)	 	Without limiting the generality of anything contained in this Agreement or the other
Financing Documents, each of the Borrowers agrees that if an Event of Default is continuing
(i) Asahi shall not be subject to any “one action” or “election of remedies” law or rule, and
(ii) all Liens and other rights, remedies or privileges provided to Asahi shall remain in full
force and effect until Asahi has exhausted all remedies against the Collateral

30

 

	 	 	and any other properties owned by the Borrowers and the Financing Documents and other
security instruments or agreements securing the Term Loan have been foreclosed, sold and/or
otherwise realized upon in satisfaction of the Borrowers’ obligations under the Financing
Documents.
	 
	(d)	 	Asahi shall have the right from time to time to partially foreclose upon any Collateral in
any manner and for any amounts secured by the Financing Documents then due and payable.
Notwithstanding one or more partial foreclosures, any unforeclosed Collateral shall remain
subject to the Financing Documents to secure payment of sums secured by the Financing
Documents and not previously recovered.

ARTICLE 9 — GUARANTEE

	9.1	 	Irrevocable Guarantee.
	 
	(a)	 	Each of the Guarantors hereby, jointly and severally, unconditionally, and irrevocably
guarantees, to Asahi and its successors and assigns, irrespective of the validity and
enforceability of the other provisions of this Agreement or any other Financing Document: (x)
the due and punctual payment of the Obligations when and as the same shall become due and
payable, whether at maturity, by acceleration, or otherwise, (the “Guarantee Obligations”).
	 
	(b)	 	Each of the Guarantors hereby agrees that its obligations hereunder shall be unconditional,
irrespective of the validity, regularity, or enforceability of the Obligations against the
Borrowers, the absence of any action to enforce the same, any waiver or consent by Asahi with
respect to any provisions hereof or thereof, any release of any other Guarantor, or any other
circumstance which might otherwise constitute a legal or equitable discharge or defense of a
Guarantor. Each of the Guarantors hereby waives the benefit of diligence, presentment, demand
of payment, filing of claims with a court in the event of insolvency or bankruptcy of any of
the Borrowers, any right to require a proceeding first against the Borrowers, protest, notice,
and all demands whatsoever, and covenants that its Guarantee Obligations shall not be
discharged except by complete performance of the Obligations. The guarantee hereunder by each
Guarantor is a guarantee of payment and not of collection.
	 
	(c)	 	The guarantee of a Guarantor hereunder will be released only upon repayment in full of all
principal and interest on the Term Loans. The Guarantors may not assign their obligations
hereunder to any other Person, provided that the Guarantee Obligations shall be binding upon
all successors and assigns of the Guarantors.

ARTICLE 10 — MISCELLANEOUS

	10.1	 	Notices.
	 
	(a)	 	All notices, requests and other communications to any party hereunder shall be in writing
(including prepaid overnight courier, facsimile transmission or similar writing) and shall be
given to such party at its address, facsimile number or e-mail address set forth on the

31

 

	 	 	signature pages hereof or at such other address, facsimile number or e-mail address as such party
may hereafter specify; provided, however, that a copy of all notices sent to the Borrowers shall
be sent to Wilmer Hale, 60 State Street, Boston, MA 02109, fax: 617-526-5000, Attn: George W.
Shuster, Jr., and a copy of all notices sent to Asahi shall be sent to Edwards Angell Palmer &
Dodge LLP, 111 Huntington Ave., Boston, MA 02199, fax: 617-517-5576, Attn: Albert L. Sokol. Each
such notice, request or other communication shall be effective (i) if given by facsimile, when
such notice is transmitted during normal business hours to the facsimile number specified by this
Section and the sender receives a confirmation during normal business hours of transmission from
the sending facsimile machine, or (ii) if given by mail, prepaid overnight courier or any other
means, when received or when receipt is refused at the applicable address specified by this
Section 10.1(a).
	 
	(b)	 	Notices and other communications to the parties hereto may be delivered or furnished by
electronic communication (including e-mail and Internet or intranet websites) pursuant to
procedures approved from time to time by Asahi. Asahi or the Borrowers may, in their
discretion, agree to accept notices and other communications to them hereunder by electronic
communications pursuant to procedures approved by it, provided, however, that approval of such
procedures may be limited to particular notices or communications.
	 
	(c)	 	Unless Asahi otherwise prescribes in writing to the Borrowers, (i) notices and other
communications sent to an e-mail address shall be deemed received upon the sender’s receipt of
an acknowledgment from the intended recipient (such as by the “return receipt requested”
function, as available, return e-mail or other written acknowledgment), and (ii) notices or
communications posted to an Internet or intranet website shall be deemed received upon the
deemed receipt by the intended recipient at its e-mail address as described in the foregoing
clause (i) of notification that such notice or communication is available and identifying the
website address therefor, provided, however, that if any such notice or other communication is
not sent or posted during normal business hours, such notice or communication shall be deemed
to have been sent at the opening of business on the next Business Day.
	 
	10.2	 	Severability. In case any provision of or obligation under this Agreement or any other
Financing Document shall be invalid, illegal or unenforceable in any jurisdiction, the
validity, legality and enforceability of the remaining provisions or obligations, or of such
provision or obligation in any other jurisdiction, shall not in any way be affected or
impaired thereby.
	 
	10.3	 	Amendments and Waivers.
	 
	 	 	No provision of this Agreement or any other Financing Document may be amended, waived or otherwise
modified unless such amendment, waiver or other modification is in writing and is signed or
otherwise approved by the Borrowers and the Asahi.
	 
	10.4	 	Confidentiality.
	 
	(a)	 	The Parties agree that the Party to whom Confidential Information (as defined in Section 10.4
(b)) is disclosed (the “Receiving Party”) shall not, except as expressly provided in this
Section 10.4, disclose to any Party or an Affiliate of a Party, or use for any purpose, any

32

 

	 	 	Confidential Information furnished to it by the other Party (the “Disclosing Party”) pursuant to
this Agreement, except in each case to the extent that it can be established by the Receiving
Party that such information:

	 	(i)	 	was, or becomes, in the public domain through no fault or action of the non-disclosing
Party;
	 
	 	(ii)	 	was already known by the non-disclosing Party, as shown by its written records;
	 
	 	(iii)	 	becomes known by the non-disclosing Party from a third party not under an obligation of
confidentiality to the disclosing Party; or
	 
	 	(iv)	 	is independently developed by the non-disclosing Party.

	 	 	No Party may issue any press release or make any public announcement concerning the
transactions contemplated by this Agreement and the existence of this Agreement without the prior
written consent of NxStage and Asahi, except to the extent required under applicable law,
including without limitation the securities laws of the United States.
	 
	 	 	The Parties’ obligations to keep information confidential pursuant to this Section 10.4 shall
survive for five (5) years after the later of (x) the repayment of the Term Loan, and (y) the
termination or expiration of the last of the following agreements: (i) the Collaboration
Agreement, (ii) the Dialyzer Production Agreement, effective as of the Effective Date, entered
into by NxStage Medical (including its Affiliates) and Asahi (including its Subsidiary defined
therein), (iii) the Supply and Purchase Agreement, effective as of the Effective Date, entered
into by NxStage Medical (including its Affiliates) and Asahi (including its Subsidiary defined
therein), and (iv) the Technology and Trademark License Agreement.
	 
	(b)	 	“Confidential Information” shall mean any non-public information disclosed by NxStage to
Asahi or Asahi to NxStage in connection with this Agreement, whether in electronic, written,
graphic, machine readable or other tangible form, that is marked or identified at the time of
disclosure as “Confidential” or “Proprietary” or is disclosed in a form other than in tangible
form and is reasonably apparent on its face to be confidential or proprietary. NxStage will
use its best efforts to reduce to written form marked as “Confidential” or “Proprietary” all
Confidential Information disclosed to Asahi in a form other than in tangible form.
Notwithstanding anything to the contrary in this Agreement, any and all NxStage Dialyzer
Manufacturing Technology, NxStage Harmony Technology and NxStage Streamline Technology (as
those terms are defined in the Collaboration Agreement) shall be deemed Confidential
Information of NxStage.
	 
	(c)	 	Notwithstanding the restrictions of Section 10.4(a), the Receiving Party may (i) use
Confidential Information disclosed to it by the Disclosing Party to the extent necessary for
the Receiving Party to perform its obligations under this Agreement and (ii) use or disclose
Confidential Information disclosed to it by the Disclosing Party to the extent such use or
disclosure is reasonably necessary in (x) exercising the rights and licenses granted hereunder
or (y) complying with applicable rule, law, regulation, judgment, decree or other order of any
court, government, or governmental agency or instrumentality or submitting

33

 

	 	 	information to tax or other governmental authorities (including without limitation the Securities
and Exchange Commission); in each case, provided that, if the Receiving Party is required to make
any such disclosure, other than pursuant to a confidentiality agreement, it will give reasonable
advance notice to the Disclosing Party of such disclosure and will use reasonable efforts to
secure confidential treatment of such information (whether through protective order or otherwise).
The Receiving Party may also disclose the Confidential Information of the Disclosing Party upon
receipt of the written consent to such disclosure by a duly authorized representative of the
Disclosing Party.
	 
	(d)	 	Each Party agrees not to disclose the terms of this Agreement to any Person not a Party or an
Affiliate of a Party without the prior written consent of NxStage and Asahi, which consent
shall not be unreasonably withheld, except (a) to such Party’s attorneys, accountants,
advisors, investors, and financing sources and their advisors and others on a need to know
basis under circumstances that reasonably ensure the confidentiality thereof, (b) to the
extent required by applicable rule, law, regulation, judgment, decree, or other order of any
court, government, or governmental agency or instrumentality, including without limitation
U.S. securities laws, (c) in connection with the enforcement of this Agreement or rights under
this Agreement, or (d) in connection with a merger, acquisition, financing transaction, or
proposed merger, acquisition, or financing transaction, or the like.
	 
	(e)	 	Each Party shall be entitled, in addition to any other right or remedy it may have, at law or
in equity, to seek an injunction, in any court of competent jurisdiction, enjoining or
restraining another Party and/or its Affiliates from any violation or threatened violation
the terms and conditions of this Section 10.4.
	 
	10.5	 	GOVERNING LAW. THIS AGREEMENT, THE NOTE AND EACH OTHER FINANCING DOCUMENT, AND ALL MATTERS
RELATING HERETO OR THERETO OR ARISING THEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR
OTHERWISE), SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE
LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES.
	 
	10.6	 	Arbitration or Jurisdiction. Any disputes, controversies or differences arising in
connection with this Agreement, including without limitation ALL ACTIONS OR PROCEEDINGS
ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE OTHER FINANCING DOCUMENTS, shall be
resolved first by amicable discussions between the Parties meeting not less than twice face to
face. In the event of failure to resolve the matter, such disputes, controversies or
differences (“Dispute”) shall be finally settled, at Asahi’s election, by (i) or (ii) below:

	 	(i)	 	Dispute shall be finally settled by arbitration to be held in (i) Tokyo, Japan, if the
arbitration is demanded by NxStage, or (ii) in Boston, Massachusetts, if the arbitration is
demanded by Asahi, under the arbitration rules of the International Chamber of Commerce by
which each Party hereto is bound. All arbitration shall be conducted in the English
language. The arbitrator’s decision will be considered as final and binding by Asahi and
NxStage; or

34

 

	 	(ii)	 	NXSTAGE HEREBY CONSENTS TO THE JURISDICTION OF ANY STATE OR FEDERAL COURT LOCATED WITHIN
NEW YORK, NEW YORK AND IRREVOCABLY AGREES THAT, SUBJECT TO ASAHI’S ELECTION, ALL ACTIONS OR
PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE OTHER FINANCING DOCUMENTS (AS
INCLUDED IN THE DISPUTE) SHALL BE LITIGATED IN SUCH COURTS.
	 
	 	 	 	NXSTAGE EXPRESSLY SUBMITS AND CONSENTS TO THE JURISDICTION OF THE AFORESAID COURTS AND WAIVES
ANY DEFENSE OF FORUM NON CONVENIENS. NXSTAGE HEREBY WAIVES PERSONAL SERVICE OF ANY AND ALL
PROCESS AND AGREES THAT ALL SUCH SERVICE OF PROCESS MAY BE MADE UPON NXSTAGE BY CERTIFIED OR
REGISTERED MAIL, RETURN RECEIPT REQUESTED, ADDRESSED TO BORROWER AT THE ADDRESS SET FORTH IN
THIS AGREEMENT AND SERVICE SO MADE SHALL BE COMPLETE TEN (10) DAYS AFTER THE SAME HAS BEEN
POSTED.
	 
	 	 	 	IN CASE OF CLAUSE (II) OF THIS SECTION 10.6, EACH PARTY HEREBY IRREVOCABLY WAIVES ANY AND ALL
RIGHT TO TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THE
FINANCING DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED THEREBY AND AGREES THAT ANY SUCH ACTION OR
PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY. EACH PARTY ACKNOWLEDGES THAT
THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS RELIED
ON THE WAIVER IN ENTERING INTO THIS AGREEMENT AND THE OTHER FINANCING DOCUMENTS, AND THAT EACH
WILL CONTINUE TO RELY ON THIS WAIVER IN THEIR RELATED FUTURE DEALINGS. EACH PARTY WARRANTS AND
REPRESENTS THAT IT HAS HAD THE OPPORTUNITY OF REVIEWING THIS JURY WAIVER WITH LEGAL COUNSEL, AND
THAT IT KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS.

	10.7	 	Counterparts; Integration. This Agreement and the other Financing Documents may be signed in
any number of counterparts, each of which shall be an original, with the same effect as if the
signatures thereto and hereto were upon the same instrument. Signatures by facsimile or by
email delivery of an electronic version of an executed signature page shall bind the parties
hereto. This Agreement and the other Financing Documents constitute the entire agreement and
understanding between the Parties and supersede any and all prior agreements and
understandings, oral or written, relating to the subject matter hereof.
	 
	10.8	 	No Strict Construction. The Parties have participated jointly in the negotiation and
drafting of this Agreement. In the event an ambiguity or question of intent or interpretation
arises, this Agreement shall be construed as if drafted jointly by the Parties and no
presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the
authorship of any provisions of this Agreement.

35

 

	10.9	 	Reinstatement. This Agreement shall remain in full force and effect and continue to be
effective should any petition or other proceeding be filed by or against the Borrowers for
liquidation or reorganization, should the Borrowers become insolvent or make an assignment for
the benefit of any creditor or creditors or should an interim receiver, receiver, receiver and
manger or trustee be appointed for all or any significant part of the Borrowers’ assets, and
shall continue to be effective or to be reinstated, as the case may be, if at any time payment
and performance of the Obligations, or any part thereof, is, pursuant to applicable law,
rescinded or reduced in amount, or must otherwise be restored or returned by any obligee of
the Obligations, whether as a fraudulent conveyance, preference or otherwise, all as though
such payment or performance had not been made. In the event that any payment, or any part
thereof, is rescinded, reduced, restored or returned, the Obligations shall be reinstated and
deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.
	 
	10.10	 	Assignment; Binding Effect. This Agreement shall be binding upon and shall be enforceable
by Asahi and the Borrowers and their respective successors and assigns. No Party shall
assign, delegate or otherwise transfer any of its rights or other obligations hereunder or
under any other Financing Document without the prior written consent of NxStage Medical and
Asahi; provided that Asahi may assign its rights and obligations hereunder or under any other
Financing Document upon the occurrence and continuance of any Event of Default hereunder, so
long as (i) Asahi provides NxStage at least thirty (30) days advance notice thereof, and (ii)
such assignment is not to a Competitor of NxStage (as defined in the Dialyzer Production
Agreement, effective as of the Effective Date, entered into by NxStage Medical, including its
Affiliates, and Asahi, including its Subsidiary defined therein).
	 
	10.11	 	Expenses
	 
	(a)	 	The Borrowers agree to pay all reasonable legal, audit and appraisal fees and all other
reasonable out-of-pocket charges and expenses incurred by Asahi (including the fees and
expenses of Asahi’s counsel, advisors and consultants) in connection with any amendments,
modifications and terminations to the Financing Documents requested by the Borrowers following
closing. The Parties shall bear their own costs and expenses in negotiating and documenting
this Agreement and the other Financing Documents and all other costs and expenses incurred
prior to the Closing Date.
	 
	(b)	 	The Borrowers agree to pay all reasonable out-of-pocket charges and expenses incurred by
Asahi (including the fees and expenses of Asahi’s counsel, advisers and consultants) following
the Closing Date in connection with the administration of this Agreement and the other
Financing Documents and the credit facilities provided hereunder and thereunder, the
administration, enforcement, protection or preservation of any right or claim of Asahi, the
termination of this Agreement, the termination of any Liens of Asahi on the Collateral, or the
collection of any amounts due under the Financing Documents, including any such charges and
expenses incurred in connection with any “work-out” or with any proceeding under the
Bankruptcy Code with respect to the Borrowers.
	 
	(c)	 	Notwithstanding Section 4.5, Section 10.11(a), and Section 10.11(b), NxStage shall not be

36

 

	 	 	required to pay to Asahi any costs, charges, premiums, penalties, or expenses in excess of
$25,000 per year.

[SIGNATURES APPEAR ON FOLLOWING PAGES]

37

 

IN WITNESS WHEREOF, intending to be legally bound, and intending that this document constitute an
instrument executed and delivered under seal, the parties hereto have caused this Agreement to be
duly executed under seal by their respective authorized officers as of the day and year first above
written.

BORROWERS:

NxStage Medical, Inc.

	 	 	 	 	 
	By:
	 	 	 	 
	Name:

	 	 

	 	 
	Title:

	 	 

	 	 
	 

	 	 

	 	 

Address:

439 South Union Street, 5th Floor

Lawrence, MA 01843

Attn: Chief Executive Officer

With copy to General Counsel

Telephone: (978) 687-4700

Facsimile: (978) 687-4825

EIR Medical, Inc.

	 	 	 	 	 
	By:
	 	 	 	 
	Name:

	 	 

	 	 
	Title:

	 	 

	 	 
	 

	 	 

	 	 

Address:

c/o NxStage Medical, Inc.

439 South Union Street, 5th Floor

Lawrence, MA 01843

Attn: Chief Executive Officer

With copy to General Counsel

Telephone: (978) 687-4700

Facsimile: (978) 687-4825

Medisystems Services Corporation

	 	 	 	 	 
	By:
	 	 	 	 
	Name:

	 	 

	 	 
	Title:

	 	 

	 	 
	 

	 	 

	 	 

Address:

c/o NxStage Medical, Inc.

439 South Union Street, 5th Floor

Lawrence, MA 01843

Attn: Chief Executive Officer

 

 

With copy to General Counsel

Telephone: (978) 687-4700

Facsimile: (978) 687-4825

Medisystems Corporation

	 	 	 	 	 
	By:
	 	 	 	 
	Name:

	 	 

	 	 
	Title:

	 	 

	 	 
	 

	 	 

	 	 

Address:

c/o NxStage Medical, Inc.

439 South Union Street, 5th Floor

Lawrence, MA 01843

Attn: Chief Executive Officer

With copy to General Counsel

Telephone: (978) 687-4700

Facsimile: (978) 687-4825

 

 

GUARANTORS:

Medimexico s. de R.L. de C.V.

	 	 	 	 	 
	By:
	 	 	 	 
	Name:

	 	 

	 	 
	Title:

	 	 

	 	 
	 

	 	 

	 	 

Address:

NxStage Verwaltungs GmbH

	 	 	 	 	 
	By:
	 	 	 	 
	Name:

	 	 

	 	 
	Title:

	 	 

	 	 
	 

	 	 

	 	 

Address:

NxStage GmbH & Co. KG

	 	 	 	 	 
	By:
	 	 	 	 
	Name:

	 	 

	 	 
	Title:

	 	 

	 	 
	 

	 	 

	 	 

Address:

Medisystems Europe S.p.A,

	 	 	 	 	 
	By:
	 	 	 	 
	Name:

	 	 

	 	 
	Title:

	 	 

	 	 
	 

	 	 

	 	 

Address:

 

 

ASAHI:

Asahi Kasei Kuraray Medical Co., Ltd.

	 	 	 	 	 
	By:
	 	 	 	 
	Name:

	 	 

	 	 
	Title:

	 	 

	 	 
	 

	 	 

	 	 

Address:

1-105, Kanda Jinbocho

Chiyoda-ku Tokyo 101-8101

Japan

Attention: President

Facsimile: +81-3-3296-3752

With copies to: President, Global Dialysis Products Division

 

 

EXHIBITS AND SCHEDULES

EXHIBITS

SCHEDULES

	 	 	 
	Schedule 3.1

	 	Corporate Information
	 	 
	Schedule 3.3

	 	Capitalization
	 	 
	Schedule 4.3

	 	Insurance
	 	 
	Schedule 4.7

	 	Notice of certain Events
	 	 
	Schedule 5.1

	 	Debt and Contingent Obligations
	 	 
	Schedule 5.2

	 	Liens
	 	 
	Schedule 5.5

	 	Investment
	 	 
	Schedule 7.1

	 	Collateral
	 	 
	Schedule 7.2

	 	Location of Collateral

 

 

Schedule 7.1 — Collateral

The Collateral consists of all of the Borrowers’ right, title and interest in and to the following,
whether now owned or hereafter created, acquired or arising, and all proceeds and products of the
following, whether now owned or hereafter acquired, wherever located:

	1.	 	All Intellectual Property, Equipment and Fixtures excluding FF&E.
	 
	2.	 	All of the Borrower’s direct and indirect equity interests in its Subsidiaries;
	 
	3.	 	All of the Borrower’s rights in real estate owned or leased by the Borrower; and
	 
	4.  All of the Borrowers’ books relating to the foregoing, and all substitutions for, additions,
attachments, accessories, accessions and improvements to, and replacements and cash insurance
proceeds of, and all direct cash proceeds from the sale of, any or all of the foregoing.

Notwithstanding the foregoing, the Collateral shall not include any licenses which are now or
hereafter held by NxStage Medical as licensee if such licenses are not assignable or capable of
being encumbered under the terms of the license or other agreement applicable thereto (unless and
solely to the extent that any such restriction on assignment or encumbrance is ineffective under
the UCC or other applicable law), without the consent of the licensor thereof or other applicable
party thereto and such consent has not been obtained after using commercially reasonable efforts to
obtain such consent; provided , however , that upon obtaining the consent of any
such licensor or other applicable party to the assignment or encumbrance of such license or other
agreement, or upon the termination or expiration of any such prohibition, such license shall
automatically be subject to the security interest granted in favor of Asahi hereunder and become
part of the Collateral.

Notwithstanding the foregoing, except as expressly set forth in Paragraph 4 hereof, the Collateral
shall not consist of any of the products or proceeds of the Collateral set forth in Paragraphs 1
through 3 above. Without limiting the foregoing, the Collateral shall not include any Goods (other
than Equipment), Inventory, Accounts, Deposit Accounts, Securities Accounts, or cash of the
Borrower or any products or proceeds of the foregoing.exv10w48

Exhibit 10.48

Confidential Materials omitted and filed separately with the 

Securities and Exchange Commission.  Asterisks denote omissions.

TECHNOLOGY AND TRADEMARK LICENSE AGREEMENT

     THIS TECHNOLOGY AND TRADEMARK LICENSE AGREEMENT (the “Agreement”), dated as of June
5, 2009 (the “Effective Date”), is made and entered into by and between NxStage Medical,
Inc., a company organized and existing under the laws of Delaware, and having offices at 439
S. Union Street, 5th Floor, Lawrence, Massachusetts 01843, United States of America,
(hereafter referred to as “NxStage”) and Asahi Kasei Kuraray Medical, Co., Ltd.,
a corporation organized and existing under the law of Japan, having its principal place of
business at 1-105, Kanda Jinbocho, Chiyoda-ku, Tokyo 101-8101, Japan (hereafter referred to as
“Asahi”). NxStage and Asahi are sometimes referred to herein individually as a “Party” and
collectively as the “Parties.”

RECITALS

     WHEREAS, NxStage owns certain intellectual property rights including manufacturing technology
to make, use, sell, and distribute Simplex Dialyzers (as defined below), Harmony Products (as
defined below) and Streamline Blood Tubing Set (as defined below) for use in Extracorporeal
Therapies (as defined below) ;

     WHEREAS, Asahi is engaged in the manufacture and sale of hollow fiber membranes for various
applications, including without limitation Asahi Membranes (as defined below);

     WHEREAS, the Parties entered into the “Letter of Intent” dated September 19, 2008 (“LOI”) in
order to negotiate agreements between the Parties under which the Parties intend to establish a
strategic alliance in the field of Extracorporeal Therapies to capitalize on Asahi’s membrane
technology and market presence and on NxStage’s market presence and experience in renal failure
technology;

     WHEREAS, as a part of such strategic alliance, Asahi desires to obtain a license under NxStage
Dialyzer Manufacturing Technology (as defined below), NxStage Harmony Technology (as defined below)
and NxStage Streamline Technology (as defined below) to make, use, sell, offer for sale and
distribute certain products, including without limitation Simplex Dialyzers incorporating Asahi
Membranes for distribution in the Territory (as defined below) for use in Extracorporeal Therapies;
and

     WHEREAS, NxStage is willing to grant to Asahi such license all on the terms and conditions set
forth in this Agreement.

     NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the Parties agree as follows:

	1.	 	DEFINITIONS

As used in this Agreement, the following terms shall have the following meanings respectively;

 

 

	1.1	 	“Affiliate” shall mean any person or entity directly or indirectly controlling, controlled
by, or under common control with, the Party in question where “control” means direct or
indirect beneficial ownership of fifty percent (50%) or more of the voting stock or equity, or
fifty percent (50%) or more of the interest in the income of such corporation or other
business entity.
	 
	1.2	 	“Asahi Membrane” shall mean any synthetic hollow fiber membrane manufactured by or for Asahi
which are suitable for use in Extracorporeal Therapies. For purposes of clarification, any
membrane manufactured by or for Asahi for use in any application other than Extracorporeal
Therapies, including without limitation plasma or apheresis therapy, is not Asahi Membrane for
purposes of this Agreement.
	 
	1.3	 	“Asia Territory” shall mean Japan, China, South Korea, Taiwan, Bangladesh, Nepal, Pakistan,
Sri Lanka, Mongolia, Brunei, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore,
Thailand, and Vietnam.
	 
	1.4	 	“Collaboration Agreement” shall mean the NxStage & Asahi Collaboration Agreement entered into
by NxStage and Asahi, effective as of the Effective Date.
	 
	1.5	 	“Confidential Information” shall mean any non-public information disclosed by one Party to
the other Party in connection with this Agreement, whether in electronic, written, graphic,
machine readable or other tangible form, that is marked or identified at the time of
disclosure as “Confidential” or “Proprietary” or is disclosed in a form other than in tangible
form and is reasonably apparent on its face to be confidential or proprietary. NxStage will
use its best efforts to reduce to written form marked as “Confidential” or “Proprietary” all
Confidential Information disclosed to Asahi in a form other than in tangible form.
Notwithstanding anything to the contrary in this Agreement, any and all NxStage Dialyzer
Manufacturing Technology, NxStage Harmony Technology, NxStage Streamline Technology and the
Deliverables shall be deemed Confidential Information of NxStage.
	 
	1.6	 	“Control” shall mean, with respect to an item of information or an intellectual property
right, possession of the ability, whether arising by ownership or license, to grant a license
or sublicense as provided in this Agreement under such item or right without violating the
terms of any written agreement with any Third Party.
	 
	1.7	 	“Deliverables” shall mean the documents describing the technical aspects of NxStage Dialyzer
Manufacturing Technology, NxStage Harmony Technology and NxStage Streamline Technology,
including without limitation the list of patents and pending patent applications thereof
(“Documentary Deliverables”), together with any proprietary equipment included within the
definition of NxStage Dialyzer Manufacturing Know-How (“Equipment Deliverables”).
	 
	1.8	 	“Dialyzer” shall mean any filter containing hollow fiber membranes intended for use in
Extracorporeal Therapies.

2

 

	1.9	 	“Extracorporeal Therapies” shall mean hemodialysis, hemofiltration, hemodiafiltration, and/or
ultrafiltration therapies. For purpose of clarification, plasma or apheresis therapies are
not the Extracorporeal Therapies for purposes of this Agreement.
	 
	1.10	 	“Harmony Products” shall mean a product for Extracorporeal Therapies developed and
manufactured by NxStage consisting of a Dialyzer that incorporates Asahi Membranes with design
and performance features of the Simplex Dialyzer, pre-attached to a Streamline Blood Tubing
Set.
	 
	1.11	 	“Intellectual Property Rights” shall mean rights in and to any and all (a) U.S. and foreign
patents and patent applications, including without limitation all divisions, substitutions,
continuations, continuations-in-part, reissues, re-examinations, and extensions thereof, (b)
copyrights, whether registered or unregistered, (c) rights in trade secrets, data, or
materials, and (d) any other intellectual or other proprietary rights of any kind now known or
hereafter recognized in any jurisdiction, whether registered or unregistered, but excluding
trademarks, service marks, trade names, trade dress, domain names, and similar rights.
	 
	1.12	 	“Loan Agreement” shall mean the Term Loan and Security Agreement entered into by NxStage and
Asahi Kasei Kuraray Medical, Co., Ltd., effective as of the Effective Date.
	 
	1.13	 	“New Facility” shall have the meaning set forth in the Production Agreement.
	 
	1.14	 	“NxStage Dialyzer Manufacturing Know-How” shall mean any technology, information, expertise,
know-how, and/or trade secrets Controlled by NxStage necessary for the manufacture of Simplex
Dialyzer(s) that is not within the NxStage Dialyzer Manufacturing Patent Rights, including
without limitation any proprietary equipment.
	 
	1.15	 	“NxStage Dialyzer Manufacturing Patent Rights” shall mean any and all rights under patents
and pending patent applications Controlled by NxStage necessary for the manufacture of Simplex
Dialyzer(s).
	 
	1.16	 	“NxStage Dialyzer Manufacturing Technology” shall mean the NxStage Dialyzer Manufacturing
Know-How and the NxStage Dialyzer Manufacturing Patent Rights.
	 
	1.17	 	“NxStage Harmony Technology” shall mean the patents, patent applications and know-how
Controlled by NxStage that are necessary for the manufacture and assembly of Harmony Products
for use in Extracorporeal Therapies.
	 
	1.18	 	“NxStage Streamline Technology’’ shall mean the patents, patent applications and know-how
Controlled by NxStage that are necessary for the manufacture and assembly of Streamline blood
tubing sets for use in Extracorporeal Therapies.
	 
	1.19	 	“NxStage System One” shall mean the NxStage System One cycler, warmer, one view accessory and
stand presently sold by NxStage for use in Extracorporeal Therapies, and any successor
equipment to NxStage System One for use in Extracorporeal Therapies.

3

 

	1.20	 	“Production Agreement” shall mean the Dialyzer Production Agreement entered into by NxStage
(including its Affiliates) and Asahi (including its Subsidiary defined therein), effective as
of the Effective Date.
	 
	1.21	 	“Simplex Dialyzers” shall mean any Dialyzer, not pre-attached to any blood tubing set or
cartridge, with the same general performance and design features (including without
limitation, an extruded body) of the Dialyzer pre-attached to the cartridge used with the
NxStage System One as of the Effective Date, and covered by NxStage’s Intellectual Property
Rights. For purposes of clarification, any Dialyzer used with NxStage System One, or any
successor equipment to NxStage System One, is not a Simplex Dialyzer for purposes of this
Agreement.
	 
	1.22	 	“Streamline Blood Tubing Set” shall mean the NxStage blood tubing set for use in
Extracorporeal Therapies that incorporates the general performance and design features of the
Streamline Blood Tubing Set marketed by NxStage as of the Effective Date.
	 
	1.23	 	“Streamline Components” shall mean components manufactured by NxStage for assembly into
Streamline Blood Tubing Sets.
	 
	1.24	 	“Term” shall have the meaning set forth in Section 6.1.
	 
	1.25	 	“Territory” shall mean all countries in the world including Asia Territory, but excluding the
United States of America (“USA”) and Canada.
	 
	1.26	 	“Third Party” shall mean any party other than NxStage, Asahi, or an Affiliate of either
NxStage or Asahi.
	 
	2.	 	License; Intellectual Property
	 
	2.1	 	Manufacturing License. 

	 	(a)	 	Subject to the terms and conditions of this Agreement, in consideration for
entering into the Loan Agreement, NxStage hereby grants to Asahi

	 	(i)	 	a license, including a right to grant sublicense rights (but only in
accordance with the terms and conditions set forth in Section 2.1(b)), under the
NxStage Dialyzer Manufacturing Technology to make, use, sell, offer for sale and
distribute Simplex Dialyzers in the Territory for use in Extracorporeal Therapies,
such license to be exclusive in the Asia Territory and non-exclusive elsewhere in
the Territory excluding the Asia Territory; provided that Asahi, and any
sublicensee of Asahi, shall have no right to make, use, offer for sale, or sell
Simplex Dialyzers anywhere in the European Union unless and until (A) the New
Facility has been constructed and (B) after Asahi has purchased at least [**]
Simplex Dialyzers in a year from such New Facility, and then only so long as Asahi
continues to purchase at least [**] Simplex Dialyzers in each calendar [**] from
such New Facility thereafter throughout the term of the Production Agreement, from
NxStage, provided that NxStage is able to supply such minimum quantities of

4

 

	 	 	 	Simplex Dialyzers meeting the Specifications as defined in the Production
Agreement from the New Facility; and

	 	(ii)	 	a license, including a right to grant sublicense rights (but only in
accordance with the terms and conditions set forth in Section 2.1(b) or Section
2.1(c)), under the NxStage Streamline Technology to assemble Streamline Blood
Tubing Sets using Streamline Components purchased from NxStage, such license to be
exclusive in the Asia Territory and non-exclusive elsewhere in the Territory
excluding the Asia Territory; and
	 
	 	(iii)	 	a license including a right to grant sublicense rights (but only in
accordance with the terms and conditions set forth in Section 2.1(b)), under the
NxStage Streamline Technology to use, sell, offer for sale, and distribute
Streamline Blood Tubing Sets assembled under the license granted under Section
2.1(a)(ii) in the Territory for use in Extracorporeal Therapies, such license to
be exclusive in the Asia Territory, and non-exclusive elsewhere in the Territory
excluding the Asia Territory; provided that NxStage exceptionally has right to
sell Streamline Blood Tubing Sets to B. Braun Melsungen AG to use, sell, offer for
sale, and distribute in the Asia Territory. Any agreement that NxStage enters
with BBraun Melsungen AG will in no way reduce Asahi’s rights granted under this
Agreement; and
	 
	 	(iv)	 	a license, including a right to grant sublicense rights (but only in
accordance with the terms and conditions set forth in Section 2.1(b) or Section
2.1(c)), under the NxStage Streamline Technology and the NxStage Harmony
Technology to use Streamline Blood Tubing Sets assembled under the license granted
under Section 2.1(a)(ii) to make Harmony Products, such license to be exclusive in
the Asia Territory and non-exclusive elsewhere in the Territory excluding the Asia
Territory; and
	 
	 	(v)	 	a license including a right to grant sublicense rights (but only in
accordance with the terms and conditions set forth in Section 2.1(b)), under the
NxStage Streamline Technology and the NxStage Harmony Technology to use, sell,
offer for sale and distribute Harmony Products made under the license granted
under Section 2.1(a)(iv) in the in the Territory for use in Extracorporeal
Therapies, such license to be exclusive in the Asia Territory and non-exclusive
elsewhere in the Territory excluding the Asia Territory;

provided that, for purposes of clarification, such licenses shall not include any right
to make, use, sell, offer for sale, or distribute any Dialyzer, Streamline Blood Tubing
Set or Harmony Product for use with NxStage System One.

	 	(b)	 	Asahi shall have the right to grant sublicenses under the license set forth in
Sections 2.1(a)(i), (ii), (iii), (iv) and (v) solely to Asahi Kasei Corporation or
Affiliates of Asahi Kasei Corporation; provided that (i) each sublicensee has agreed to
be bound by all applicable terms and conditions set forth in this Agreement (including
without limitation Asahi’s confidentiality obligations), (ii) the terms and conditions
of each

5

 

	 	 	 	such sublicense are consistent with, and no less restrictive than, the terms and
conditions of this Agreement, and (iii) NxStage is designated as a Third Party
beneficiary of such sublicense and, consistent with the terms and conditions of this
Agreement, entitled to enforce the terms and conditions of such sublicense with respect
to such sublicensee in the event that Asahi elects not to enforce such terms and
conditions of this Agreement. Notwithstanding anything to the contrary, any such
sublicense shall not be sublicenseable.

	 	(c)	 	Asahi shall have the right to grant sublicenses under the licenses set forth in
Section 2.1(a)(ii) and 2.1(a)(iv) to Third Parties; provided that (i) each sublicensee
has agreed to be bound by all applicable terms and conditions set forth in this
Agreement (including without limitation Asahi’s confidentiality obligations), (ii) the
terms and conditions of each such sublicense are consistent with, and no less
restrictive than, the terms and conditions of this Agreement, and (iii) NxStage is
designated as a Third Party beneficiary of such sublicense and, consistent with the
terms and conditions of this Agreement, entitled to enforce the terms and conditions of
such sublicense with respect to such sublicensee in the event that Asahi elects not to
enforce such terms and conditions of this Agreement. Notwithstanding anything to the
contrary, any such sublicense shall not be sublicenseable.
	 
	 	(d)	 	No later than [**] after the Effective Date, NxStage shall at Asahi’s request
provide a tour of its filter production facility and review key processes and
technology.. Within [**] after the date of such tour, NxStage, with input from Asahi,
will provide a written list of Deliverables and deliver all Documentary Deliverables to
Asahi. At a commercially reasonable schedule and time to be mutually agreed upon by
the Parties, NxStage will deliver the Equipment Deliverables to Asahi. Any Equipment
Deliverables shall be provided by NxStage to Asahi at NxStage’s cost plus [**] percent
([**]%) only after Asahi has exercised the option to construct a New Facility and made
the Phase II Capital available under the Production Agreement. NxStage shall provide
reasonable assistance to enable Asahi to implement the manufacture of Simplex
Dialyzers, such assistance to be provided via telephone conference and, to the extent
deemed necessary by Asahi, [**], visits to Asahi’s manufacturing facilities, and, as
requested by Asahi, [**], accommodating Asahi’s personnel at NxStage’s manufacturing
facilities. At any time during the Term after a period of [**] after the Effective
Date, Asahi may request that NxStage provide additional, reasonable assistance with
respect to the manufacture of Simplex Dialyzers, such assistance to be provided [**].
	 
	 	(e)	 	In the event Asahi exercises its rights under Section 14.3.2 or 15.6.3 of the
Production Agreement, NxStage shall, on such exercise, grant to Asahi a royalty-free
and non-exclusive license under all NxStage intellectual property (including NxStage
Dialyzer Manufacturing Technology) necessary to manufacture Simplex Dialyzers in the
New Facility. Such license shall be added to and included in the licenses set forth in
(a) of this Section 2.1. Within [**] after such event, NxStage shall disclose to
Asahi, if any, all such NxStage intellectual property.

6

 

	2.2	 	Improvement.

	 	(a)	 	In this Section 2.2, “Improvement” shall mean any improvement or modification
to the NxStage Dialyzer Manufacturing Technology, NxStage Harmony Technology and
NxStage Streamline Technology, (including designs, utilities, manufacturing or methods)
which either NxStage (including its Affiliates) or Asahi (including its Affiliates,
Asahi Kasei Corporation, and Affiliates of Asahi Kasei Corporation) develops or obtains
in the course of using the NxStage Dialyzer Manufacturing Technology, NxStage Harmony
Technology and NxStage Streamline Technology and which excludes any ideas, discoveries,
developments and inventions that are conceived, reduced to practice, or otherwise
developed under the Collaboration Agreement.
	 
	 	(b)	 	If NxStage (including its Affiliates) develops or obtains any Improvement
during [**] period after the Effective Date, NxStage shall free of charge grant to
Asahi a license thereunder subject to the same conditions set forth herein. If Asahi
(including its Affiliates, Asahi Kasei Corporation and Affiliates of Asahi Kasei
Corporation) develops or obtains any Improvement during [**] period after the Effective
Date, Asahi shall free of charge grant to NxStage a license thereunder exclusively in
USA and Canada and non-exclusively in the Territory excluding Asia Territory.
	 
	 	(c)	 	If either NxStage (including its Affiliates) or Asahi (including its
Affiliates, Asahi Kasei Corporation and Affiliates of Asahi Kasei Corporation) develops
or obtains any Improvement during the Term after the five years period set forth in (b)
of this Section 2.2, such developing Party may at its discretion disclose to the other
Party such Improvement. If the other Party requests such developing Party to obtain a
license of such Improvement, such developing Party may at its discretion negotiate with
the other Party to grant such license.

	2.3	 	Manufacture of Streamline, Streamline Components and Harmony Products.
Notwithstanding anything to the contrary, in connection with the exclusive license granted by
NxStage to Asahi under Section 2.1(a), NxStage will manufacture Streamline Blood Tubing Sets
and/or Streamline Components, or Harmony Products for sale to Asahi for sale by Asahi
exclusively in the Asia Territory, and Asahi shall have no right to manufacture any Streamline
Components.

	 	(a)	 	If Asahi elects to have NxStage manufacture and supply Streamline Blood Tubing
Sets and/or Streamline Components or Harmony Products for sale by Asahi exclusively in
the Asia Territory, Asahi shall provide written notice thereof to NxStage within [**]
after the Effective Date.
	 
	 	(b)	 	In the event that Asahi provides written notice to NxStage in accordance with
(a) of this Section 2.3, the Parties shall, within [**], meet to discuss in good faith
the terms of a supply agreement for providing such product(s) to Asahi. Product
transfer pricing and terms for each such product shall be [**].

7

 

	2.4	 	Trademark License. 

	 	(a)	 	NxStage hereby grants to Asahi a non-exclusive and non-transferable license to
use the NxStage trademarks, trade names and logos (hereinafter collectively referred to
as “Trademarks”) set forth in Exhibit 2.4(a) solely in connection with the
marketing, promotion, and sale of Simplex Dialyzers (including Simplex Dialyzers
manufactured by NxStage for Asahi under the Production Agreement). Streamline Blood
Tubing Sets and Harmony Products (hereinafter collectively referred to as “Contract
Products”) for use in Extracorporeal Therapies in accordance with this Agreement. All
ownership and goodwill arising out of the use of the Trademarks by Asahi shall vest in
and inure solely to the benefit of NxStage. Asahi agrees to conduct business related
to such Simplex Dialyzers in a manner that reflects favorably at all times on the
products, goodwill, and reputation of NxStage.
	 
	 	(b)	 	All representations of the Trademarks that Asahi intends to use shall first be
submitted to NxStage for approval (which shall not be unreasonably withheld or delayed)
of design, color, and other details or shall be exact copies of those used by NxStage.
In addition, all representations of the Trademarks that are used by Asahi shall comply
with the reasonable usage guidelines provided by NxStage. Asahi shall submit to a
NxStage representative promotional materials, packaging and product labels for review
and comment by NxStage prior to their first use and prior to any subsequent change or
addition. NxStage may change the Trademarks and usage guidelines, to be used by Asahi
only upon [**] prior written notice to Asahi, setting forth in such notice the changes.
	 
	 	(c)	 	Inspection. Asahi will permit duly authorized representatives of
NxStage to inspect Contract Products and related promotional, sales and advertising
materials of Asahi at Asahi’s premises using the Trademarks at all reasonable times, in
a reasonable manner, and upon reasonable advance notice, for the sole purpose of, and
strictly limited to, ascertaining or determining compliance with this Sections 2.4.
	 
	 	(d)	 	Ownership of Trademark. The Parties acknowledge NxStage’s exclusive
right, title and interest in and to the Trademarks and any registration that may issue
thereon, and will not intentionally at any time do or cause to be done any act or thing
contesting or in any way impairing or tending to impair any part of such right, title
and interest. In connection with the use of the Trademarks, Asahi shall not in any
manner represent that it has any ownership in the Trademarks or registrations thereof,
and shall acknowledge that use of the Trademarks shall inure to the benefit of NxStage.

	2.5	 	Prosecution and Maintenance. NxStage shall, at its own cost and expense, use
commercially reasonable efforts to file, prosecute and maintain the NxStage Dialyzer
Manufacturing Patent Rights and the Trademarks in the Territory. In satisfying this
obligation, NxStage shall exercise its sole reasonable discretion, it being understood that
patents shall not be abandoned without NxStage consulting in good faith with Asahi first.
	 
	2.6	 	Third Party’s Infringement. In the event any Third Party infringes NxStage’s right,
title or interest in the NxStage Dialyzer Manufacturing Patent Rights or the Trademarks

8

 

	 	 	(“NxStage’s right”), Asahi shall reasonably cooperate with NxStage in NxStage’s defense of
NxStage’s rights at NxStage’s expense. Asahi shall notify NxStage of any infringements of
NxStage’s rights of which Asahi is aware. NxStage has the exclusive right to prosecute and
defend all suits or proceedings before governmental agencies which involve in any way
validity of, title to, or infringement of NxStage’s rights.

	2.7	 	Third Party’s Right. NxStage agrees (i) to defend any and all claims, actions and
suits alleging that the manufacture, having manufactured, use or sale of the Simplex Dialyzer
by Asahi in the Territory infringes any patent or other intellectual property right of any
Third Party during the Term; and (ii) to hold Asahi harmless from all loss, damage, expense
and liability on account of any such infringement, provided that NxStage shall have prompt
notice of the commencement of any such action or suit and full opportunity to defend the same.
Asahi shall, at its expense, be entitled to participate in the defense of any such, claim
action or suit through counsel selected by it. NxStage shall have the opportunity to settle
all such litigation under commercially reasonable terms, within NxStage’s sole discretion.
	 
	2.8	 	No Other Rights. Except as expressly set forth in this Agreement, neither Party
grants to the other Party any right or license, express or implied, under any of such Party’s
Intellectual Property Rights. Each Party covenants that it shall use and practice the
Intellectual Property Rights granted to such Party by the other Party under this Section 2
only for the purposes expressly provided in this Section 2 and for no other purpose.
	 
	3.	 	Consideration of License
	 
	3.1	 	In consideration of the rights and licenses granted by NxStage to Asahi hereunder, Asahi
shall not be required to pay any royalty or fee other than entering into the Loan Agreement.
	 
	4.	 	CONFIDENTIALITY
	 
	4.1	 	Confidentiality. The Parties agree that the Party to whom Confidential Information
is disclosed (the “Receiving Party”) shall not, except as expressly provided in this Section
4, disclose to any Third Party, or use for any purpose, any Confidential Information furnished
or disclosed to it by the other Party (the “Disclosing Party”) pursuant to this Agreement,
except in each case to the extent that it can be established by the Receiving Party that such
information:

	 	(a)	 	was, or becomes, in the public domain through no fault or action of the
Receiving Party;
	 
	 	(b)	 	was already known by the Receiving Party without an obligation of
confidentiality, as shown by its written records;
	 
	 	(c)	 	becomes known by the Receiving Party from a Third Party not under an obligation
of confidentiality to the disclosing Party; or
	 
	 	(d)	 	is independently developed by the Receiving Party without use or reference to
the disclosing Party’s Confidential Information.

9

 

Neither Party may issue any press release or make any public announcement concerning the
transactions contemplated by this Agreement and the existence of this Agreement without the
prior written consent of the other Party, except to the extent required under applicable
law, including without limitation the securities laws of the United States.

Notwithstanding the provisions of this Article 4, Asahi may disclose (a) Confidential
Information disclosed by NxStage and (b) the terms hereof to any party of Asahi Kasei
Corporation and Affiliates of Asahi Kasei Corporation on a need to know basis only after
such party to be disclosed agrees to the same obligations as set forth herein as the
obligations of Asahi.

The Parties’ obligations to keep information confidential shall survive for [**] after the
termination or expiration of the last of the following agreements: (i) this Agreement, (ii)
the Production Agreement, (iii) the Supply and Purchase Agreement, effective as of the
Effective Date, entered into by NxStage (including its Affiliates) and Asahi (including its
Subsidiary defined therein), and (iv) the NxStage and Asahi Collaboration Agreement,
effective as of the Effective Date, entered into by NxStage and Asahi.

	4.2	 	Permitted Use and Disclosures. Notwithstanding the restrictions of Section 4.1, the
Receiving Party may (a) use Confidential Information disclosed to it by the Disclosing Party
to the extent necessary for the Receiving Party to perform its obligations under this
Agreement and (b) use or disclose Confidential Information disclosed to it by the Disclosing
Party to the extent such use or disclosure is reasonably necessary in (i) exercising the
rights and licenses granted hereunder, (ii) prosecuting or defending litigation, (iii)
complying with applicable rule, law, regulation, judgment, decree or other order of any court,
government, or governmental agency or instrumentality or submitting information to tax or
other governmental authorities (including without limitation the Securities and Exchange
Commission), (iv) preparing, filing, and prosecuting patent applications, or (v) making a
permitted sublicense or otherwise exercising license rights expressly granted pursuant to this
Agreement; in each case, provided that, if the Receiving Party is required to make any such
disclosure, other than pursuant to a confidentiality agreement, it will give reasonable
advance notice to the Disclosing Party of such disclosure and will use reasonable efforts to
secure confidential treatment of such information (whether through protective order or
otherwise), except to the extent inappropriate with respect to patent applications. The
Receiving Party may also disclose the Confidential Information of the Disclosing Party upon
receipt of the written consent to such disclosure by a duly authorized representative of the
Disclosing Party.
	 
	4.3	 	Nondisclosure of Terms. Each Party agrees not to disclose the terms of this
Agreement to any Third Party without the prior written consent of the other Party, which
consent shall not be unreasonably withheld, except (a) to such Party’s attorneys, accountants,
advisors, investors, and financing sources and their advisors and others on a need to know
basis under circumstances that reasonably ensure the confidentiality thereof, (b) to the
extent required by applicable rule, law, regulation, judgment, decree, or other order of any
court, government, or governmental agency or instrumentality, including without limitation
U.S. securities laws, (c) in connection with the enforcement of this Agreement or rights under

10

 

	 	 	this Agreement, or (d) in connection with a merger, acquisition, financing transaction, or
proposed merger, acquisition, or financing transaction, or the like.

	4.4	 	Injunction. Each Party shall be entitled, in addition to any other right or remedy
it may have, at law or in equity, to seek an injunction, in any court of competent
jurisdiction, enjoining or restraining the other Party and/or its Affiliates from any
violation or threatened violation the terms and conditions of this Section 4.
	 
	5.	 	REPRESENTATIONS AND WARRANTIES; INDEMNITY; LIMITATION OF LIABILITY; DISCLAIMER
	 
	5.1	 	Representations and Warranties. 
	 
	5.1.1	 	NxStage and Asahi each hereby represents and warrants as follows:

	 	(a)	 	It is a corporation duly organized, validly existing and in good standing under
the laws of the jurisdiction of its incorporation and has the full corporate power and
authority to enter into this Agreement and perform its agreements and covenants to be
performed hereunder;
	 
	 	(b)	 	The execution and delivery of this Agreement and its performance of the
covenants and agreements hereunder have been duly authorized by all necessary corporate
action and, when executed and delivered, shall be valid and binding upon it; and
	 
	 	(c)	 	Neither the execution and delivery of this Agreement nor the performance by it
of the transactions contemplated herein will violate any provision of its certificate
of incorporation or bylaws or any rule, law, regulation, judgment, decree, or other
order of any court, government, or governmental agency or instrumentality, or conflict
with or result in any breach of any of the terms of, or the creation or imposition of
any charge or encumbrance pursuant to, any contract or agreement to which it is a party
or by which it, or any of its assets and properties are bound.

	5.1.2	 	Representations and Warranties. NxStage hereby represents and warrants that the
NxStage Dialyzer Manufacturing Technology, the NxStage Streamline Technology and the NxStage
Harmony Technology, as existing as of the Effective Date, includes all of the technology used
by NxStage in the manufacture of Dialyzers, Streamline Blood Tubing Sets and Harmony Products,
as applicable, on the Effective Date.
	 
	5.2	 	Indemnity.

	 	(a)	 	Each Party (the “Indemnifying Party”) agrees to indemnify and hold the other
Party (the other Party and its Affiliates and the officers, employees and directors of
the other Party and its Affiliates, collectively hereinafter referred to as the
“Indemnified Party”) harmless from any and all Third Party claims, damages, costs and
expenses that may be claimed or asserted against the Indemnified Party, arising out of

11

 

	 	 	 	Indemnifying Party’s manufacture, use or sale of Simplex Dialyzers, except to the
extent that any such Third Party claim, damage, cost or expense is the direct
consequence of Indemnified Party’s negligence or willful misconduct. The obligation of
Indemnifying Party to indemnify the Indemnified Party pursuant to this Section 5.2(a)
shall be conditioned upon the Indemnified Party giving reasonably prompt notice of any
such claim, damage, cost or expense for indemnification to the Indemnifying Party, and
giving the Indemnifying Party authority to conduct the defense of any action in its
sole discretion including deciding on settlement of any action; provided, however, that
the Indemnified Party may retain additional counsel at its own expense and participate
in any such litigation.
	 
	 	(b)	 	In order to discharge the obligations set forth in Section 5.2(a), each Party
agrees to obtain and keep in force during the Term, product liability insurance with a
limit of liability of not less than $5,000,000. The insurance policies evidencing such
insurance shall be endorsed to name the other Party as an additional insured and
provide that the insurer will endeavor to provide written notification to the other
Party by the insurer of not less than thirty (30) days prior to cancellation,
expiration or material modification of such insurance. A certificate of insurance from
each Party’s insurer evidencing compliance with the requirements of this Section 5.2(b)
shall be given to the other Party upon the execution of this Agreement.

	5.3	 	Limitation. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR TO ANYONE
CLAIMING THROUGH OR UNDER THE OTHER PARTY, FOR ANY LOST PROFITS, LOST SAVINGS, PRODUCT OR
EQUIPMENT DOWNTIME, OR LOST DATA, OR FOR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL, OR INDIRECT
DAMAGES OF ANY KIND ARISING FROM OR RELATING TO ANY DELIVERABLES OR SERVICES PROVIDED OR
LICENSES GRANTED UNDER THIS AGREEMENT, OR THIS AGREEMENT, EVEN IF SUCH PARTY HAS BEEN ADVISED
OF THE POSSIBILITY OF SUCH DAMAGES. The limitation of damages set forth above in this Section
5.3 shall not apply to a Party’s liability arising from a breach of Section 4, a breach of
license restrictions under this Agreement, or to any claim of infringement or misappropriation
by a Party of any Intellectual Property Rights owned or otherwise controlled by the other
Party.
	 
	5.4	 	Disclaimer. EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY
REPRESENTATIONS, WARRANTIES, OR COVENANTS OF ANY KIND, WHETHER EXPRESS, IMPLIED, OR STATUTORY,
WITH RESPECT TO ANY SERVICES OR DELIVERABLES PROVIDED HEREUNDER OR ANY DELIVERABLES OR
SERVICES PROVIDED OR LICENSES GRANTED UNDER THIS AGREEMENT, OR THIS AGREEMENT, AND HEREBY
EXPRESSLY DISCLAIMS ANY AND ALL SUCH REPRESENTATIONS, WARRANTIES, AND CONDITIONS, INCLUDING
ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, OR
NON-INFRINGEMENT.

12

 

	6.	 	TERM; TERMINATION
	 
	6.1	 	Term. The term of this Agreement shall commence on the Effective Date, and, unless
terminated earlier as provided in Section 6.2, shall continue in full force and effect until
expiration of all claims in all issued patents of the NxStage Dialyzer Manufacturing Patent
Rights, the NxStage Harmony Technology and/or the NxStage Streamline Technology (the “Term”)
and, thereafter, the rights and obligations of the Parties will be as set forth in Section
6.3.
	 
	6.2	 	Termination for Material Breach or Insolvency. Either Party may terminate this
Agreement in the event the other Party shall have materially breached or defaulted in the
performance of any of its material obligations hereunder, and such default shall have
continued for [**] after written notice thereof was provided to the breaching Party by the
non-breaching Party. Any termination shall become effective at the end of such [**] period
unless the breaching Party (or any other party on its behalf) has cured any such breach or
default prior to the expiration of the [**] period. If a petition in bankruptcy or for
corporate reorganization or for any similar relief is filed by or against either Party (and in
the case of involuntary proceedings, is not successfully contested), or a receiver is
appointed with respect to any of the material assets of such Party, or a liquidation
proceeding is commenced by or against such Party (and, in the case of involuntary proceedings,
is not successfully contested) (collectively, hereinafter defined as “Insolvency”), then the
other Party may terminate this Agreement upon thirty (30) days prior notice; provided that
such termination right shall not extend if the Party is in Chapter 11 rather than Chapter 7
bankruptcy proceedings under the bankruptcy law of the USA or in similar bankruptcy
proceedings of proper law in any other country.
	 
	6.3	 	Effect of Expiration or Termination.

	 	(a)	 	Expiration or termination of this Agreement for any reason shall not release
either Party from any liability or obligation that, at the time of expiration or such
termination, has already accrued to the other Party or that is attributable to a period
prior to expiration or such termination, nor shall it preclude either Party from
pursuing any right and/or remedy that such Party may have hereunder, at law or in
equity, with respect to any breach of this Agreement.
	 
	 	(b)	 	Upon any termination of this Agreement, but not expiration of this Agreement,
each Party shall promptly return to the other Party all Confidential Information
received from such other Party except one (1) copy of which may be retained for
archival purposes or as necessary to exercise the rights and satisfy the obligations of
the Party retaining such copy, and for no other reason.
	 
	 	(c)	 	Except as provided below, Sections 1, 2.3, 4, 5.2, 5.3, 5.4, 6.3 and 7 shall
survive the expiration or the termination of this Agreement for any reason. Sections
2.1, 2.2, 2.3 and 2.4 shall survive the expiration of this Agreement, but not the
termination of this Agreement pursuant to Section 6.2.

13

 

	 	(d)	 	Notwithstanding anything to the contrary herein, upon the expiration of this
Agreement pursuant to Section 6.1, (i) Asahi retains its rights and licenses granted by
NxStage to Asahi under Sections 2.1 and 2.2, but on a non-exclusive basis thereafter in
the Territory and (ii) NxStage retains its rights and licenses granted by Asahi to
NxStage under Section 2.2, but on a non-exclusive base thereafter in USA, Canada and
the Territory excluding Asia Territory.
	 
	 	(e)	 	Notwithstanding anything to the contrary herein, (i) upon the termination of
this Agreement by Asahi for a reason due to NxStage’s material breach or default hereof
pursuant to Section 6.2, or (ii) upon the termination of this Agreement as a
consequence of NxStage being in Chapter 7 bankruptcy proceedings under the bankruptcy
law of the USA pursuant to Section 6.2 or while under similar bankruptcy liquidation
rather than reorganization proceedings under the bankruptcy laws of any other country,
or (iii) upon the termination of this Agreement under the direction and consent of a
bankruptcy trustee while NxStage is in Chapter 11 rather than Chapter 7 bankruptcy
proceedings under the bankruptcy laws of the USA or while under similar bankruptcy
reorganization rather than liquidation proceedings under the bankruptcy laws of any
other country, or (iv) upon the termination of this Agreement for any other reason due
to NxStage’s Insolvency pursuant to Section 6.2, Asahi shall retain its rights and
licenses granted by NxStage to Asahi under Sections 2.1 and 2.2 on and after such
termination, and Asahi shall have (i) a right of first refusal against any terms
offered and agreed to by any Third Party to obtain a license under the rights granted
to Asahi under Sections 2.1 and 2.2 to practice such rights in the USA and Canada, and
(ii) a right to practice such first refusal rights until the earlier of [**] after the
initiation of NxStage’s bankruptcy proceedings, or the execution of such right of first
refusal, in exchange for the payment by Asahi to NxStage of [**] dollars ($[**]).
Except as expressly set forth in this Section 6.3, upon such termination, NxStage’s
rights and licenses granted by Asahi to NxStage under Section 2.2 shall immediately
terminate.
	 
	 	(f)	 	Except as expressly set forth in this Section 6.3, (i) upon the termination of
this Agreement by NxStage for a reason due to Asahi’s material breach or default hereof
pursuant to Section 6.2, or (ii) upon the termination of this Agreement as a
consequence of Asahi being in Chapter 7 bankruptcy proceedings under the bankruptcy law
of the USA pursuant to Section 6.2 or while under similar bankruptcy liquidation rather
than reorganization proceedings under the bankruptcy laws of any other country, or
(iii) upon the termination of this Agreement under the direction and consent of a
bankruptcy trustee while Asahi is in Chapter 11 rather than Chapter 7 bankruptcy
proceedings under the bankruptcy laws of the USA or while under similar bankruptcy
reorganization rather than liquidation proceedings under the bankruptcy laws of any
other country, or (iv) upon the termination of this Agreement for any other reason due
to Asahi’s Insolvency pursuant to Section 6.2, Asahi’s rights and licenses granted by
NxStage to Asahi under Article 2, including without limitation, Sections 2.1, 2.2, 2.3
and 2.4 shall immediately terminate.

	7.	 	MISCELLANEOUS

14

 

	7.1	 	Relationship. Each Party is an independent contractor, and neither Party is the
agent, representative or partner of the other Party. Neither Party has the authority or power
to bind or contract in the name of or to create any liability against the other Party in any
way or for any purpose. Each Party expressly reserves the right to enter other similar
agreements with other Parties on the same or on different terms.
	 
	7.2	 	Assignment and Change of Control.
	 
	7.2.1	 	In this Section 7.2, the following terms shall have the following meanings respectively;

	 	(a)	 	“Change of Control” means any one of the following events: (i) any person or
two or more persons acting in concert shall have acquired beneficial ownership,
directly or indirectly, of more than fifty percent (50%) of the total voting power of
the stock then outstanding of the Party normally entitled to vote in elections of
directors; (ii) the Party consolidates with or merges into another entity, or any
entity consolidates with or merges into the Party, in either event pursuant to a
transaction in which more than fifty percent (50%) of the total voting power of the
stock outstanding of the surviving entity normally entitled to vote in elections of
directors is not held by the parties holding at least fifty percent (50%) of such total
voting power of the Party preceding such consolidation or merger; or (iii) the Party
conveys, transfers or leases all or substantially all of its assets to a another entity
not an Affiliate of the Party. Notwithstanding the foregoing, the acquisition/ownership
of more than 50% by any Existing Stockholder or two or more Existing Stockholders
(meaning any stockholder of NxStage Medical as of the Effective Date which beneficially
owns, together with its Affiliates, more than five percent (5%) of the outstanding
capital stock of NxStage Medical as of the Effective Date) will not constitute a Change
of Control. As soon as available after the Effective Date, NxStage shall provide Asahi
with the list of the Existing Stockholders.
	 
	 	(b)	 	Competitor of Asahi” means an individual or entity that, as of the date of the
Change of Control, competes with Asahi in the business of the same or competitive
products of Dialyzers.
	 
	 	(c)	 	“Competitor of NxStage” means an individual or entity that, as of the date of
the Change of Control, competes with NxStage in the business of the same or competitive
products of the NxStage System One.
	 
	 	(d)	 	“Permitted Assignee” means (i) Affiliates of the assigning Party, including
Asahi Kasei Corporation and Affiliates of Asahi Kasei Corporation, in case of Asahi
being the assigning Party, and (ii) Third Parties, including Asahi Kasei Corporation
and Affiliates of Asahi Kasei Corporation, in case of Asahi being the assigning Party,
other than a Competitor of the other Party, to whom the assigning Party transfers all
or substantially all of the products, business and services to which this Agreement
relates.

	7.2.2	 	Assignment and Change of Control. This Agreement and the covenants it contains will
be binding and inure to the benefits of the Parties and their heirs, assigns, successors and
legal

15

 

representatives. Except as provided below, (i) no Party may assign this Agreement, as
amended from time to time, other than to a Permitted Assignee, and (ii) it shall be a
condition of any such assignment that the assignee shall, in writing, assume all obligations
of assigning Party under this Agreement. In the event that an assignee is a Competitor of
the other Party to whom the assigning Party transfers all or substantially all of the
products, business and services to which this Agreement relates, or in the event that a
Change of Control event of the assigning Party arises where the surviving entity is a
Competitor of the other Party, the assigning Party realizes that, if an assignee or
surviving entity is a Competitor, this may significantly affect the business of the other
Party and performance under this Agreement. In the event that an assignee is a Competitor
of either NxStage or Asahi, or a Change of Control event of either NxStage or Asahi arises
where the surviving entity is a Competitor, the Parties shall meet to discuss what changes,
if any, will be required in this Agreement and the treatment of this Agreement. Despite
consultation, if the Parties cannot find a mutually acceptable solution, notwithstanding
anything herein to the contrary, this Agreement shall nonetheless survive such assignment or
Change of Control; provided that if Asahi is the non-assigning Party, Asahi may elect to
immediately revoke, upon the closing date of such assignment or Change of Control and upon
written notice to the assigning Party all license rights granted in Improvements under
Section 2.2 prior to the date of the closing of such assignment or Change of Control; and
provided further, if Asahi is the non-assigning Party, the obligations to purchase Simplex
Dialyzers from NxStage under Section 2.1(a)(i) shall terminate upon the closing of such
assignment or Change of Control. License rights and obligations with respect to future
Improvements from and after the closing date of any assignment or Change of Control of
either NxStage or Asahi shall terminate immediately on the date of such closing.

	7.3	 	Waiver. Failure or neglect by either Party to enforce at any time any of the
provisions hereof shall not be construed nor shall be deemed to be a waiver of such Party’s
rights hereunder nor in any way affect the validity of the whole or any part of this Agreement
nor prejudice such Party’s rights to take subsequent action.
	 
	7.4	 	Notices. Any notice required or permitted to be given under this Agreement shall be
in writing, shall make specific reference to this Agreement, and shall be addressed to the
appropriate Party at the address specified below or such other address as may be specified by
such Party in writing in accordance with this Section 7.4, and shall be deemed to have been
given for all purposes (a) when received, if hand-delivered or sent by a reputable overnight
delivery service, (b) on the day of sending by facsimile, if followed by mailing by first
class certified or registered mail, postage prepaid, return receipt requested, or (c) five (5)
days after mailing, if mailed by first class certified or registered mail, postage prepaid,
return receipt requested.

16

 

If to NxStage, to:

NxStage Medical, Inc.

439 S. Union Street, 5th Floor

Lawrence, Massachusetts 01843

United States of America

Facsimile: 978-687-4805

Attention: President, with a copy to General Counsel

If to Asahi, to:

Asahi Kasei Kuraray Medical, Co., Ltd.

[1-105, Kanda Jinbocho]

[Chiyoda-ku Tokyo 101-8101]

Japan

Facsimile: +81-3-3296-3752

Attention: President, with a copy to President, Global

Dialysis Products Division

	7.5	 	Severability. Any term or provision of this Agreement that is held to be invalid,
void, or unenforceable in any situation in any jurisdiction will not affect the validity or
enforceability of the remaining terms and provisions hereof or the validity or enforceability
of the invalid, void, or unenforceable term or provision in any other situation or in any
other jurisdiction. If any term or provision of this Agreement is declared invalid, void, or
unenforceable, the Parties agree that the authority making such determination will have the
power to and shall, subject to the discretion of such authority, reduce the scope, duration,
area or applicability of the term or provision, to delete specific words or phrases, or to
replace any invalid, void, or unenforceable term or provision with a term or provision that is
valid and enforceable and that comes closest to expressing the original intention of the
invalid or unenforceable term or provision.
	 
	7.6	 	Governing Law.  This Agreement shall be governed by and construed and enforced in
accordance with the laws of the State of New York, USA. The Convention on Contracts for the
International Sales of Goods (CISG) and any related subsequent conventions shall not apply to
sales hereunder.
	 
	7.7	 	Dispute Resolution. Any disputes, controversies or differences arising in connection
with this Agreement shall be resolved first by amicable discussions between the Parties
meeting not less than twice face to face. In the event of failure to resolve the matter, such
disputes, controversies or differences shall be finally settled by arbitration to be held: (i)
in Tokyo, Japan, if the arbitration is demanded by NxStage; or (ii) in Boston, Massachusetts,
if the arbitration is demanded by Asahi under the arbitration rules of the International
Chamber of Commerce by which each Party hereto is bound. All arbitration shall be conducted in
the English language. The arbitrator’s decision will be considered as final and binding by
Asahi and NxStage.
	 
	7.8	 	Compliance with Law. In performing its duties under this Agreement, each Party shall
at all times comply with all applicable international, federal, state, and local laws.
Without

17

 

limiting any of the foregoing, each Party agrees that it shall not download, export, or
re-export any software or technical data received hereunder, regardless of the manner in
which received, (a) into, or to a national or resident of, any country to which the United
States has embargoed goods, or (b) to anyone on the United States Treasury Department’s list
of Specially Designated Nationals or the U.S. Commerce Department’s Table of Denial Orders.

	7.9	 	Headings; Construction. The headings of each section in this Agreement have been
inserted for convenience of reference only and are not intended to limit or expand on the
meaning of the language contained in the particular section. The words “hereof,” “herein” and
“herewith” and words of similar import will, unless otherwise stated, be construed to refer to
this Agreement as a whole and not to any particular provision of this Agreement, and section
and exhibit references are references to the sections and exhibits of this Agreement, unless
otherwise specified. Any reference to a Party will include such Party’s permitted successors
and permitted assigns.
	 
	7.10	 	Counterparts. This Agreement may be executed in one or more counterparts (whether
delivered by facsimile or otherwise), each of which will be considered one and the same
agreement and will become effective when counterparts have been signed by each of the Parties
and delivered to the other Party.
	 
	7.11	 	Amendments.  Any agreement on the part of a Party to any extension, waiver,
amendment, modification, or supplement of this Agreement or its rights hereunder will be valid
only if set forth in an instrument in writing signed on behalf of such Party.
	 
	7.12	 	Entire Agreement. This Agreement with its exhibits, (a) constitutes the entire
agreement and supersedes, as of the Effective Date, all prior and contemporaneous agreements,
negotiations, arrangements, and understandings, both written and oral with respect to the
subject matter hereof, and (b) is not intended to confer upon any person or entity, other than
the Parties, any rights, benefits, or remedies of any nature whatsoever.

[Signature Page Follows]

18

 

     IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed by their
authorized representatives as of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	NXSTAGE MEDICAL, INC.	 	ASAHI KASEI KURARAY MEDICAL, CO., LTD	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Jeffrey H. Burbank  	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	Name: Jeffrey H. Burbank
	 	 	 	 	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Title:   President and Chief Executive Officer
	 	 	 	 	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 

			
	EXHIBIT 2.4(a)	 	TRADEMARKS

 

 

Exhibit 2.4(a) Trademarks

NxStage®

	 	 	 
	

	®

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}]]